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Abstract 
In the event of peripheral infection, aged mice exhibit a heightened central 
inflammatory cytokine response, as well as prolonged behavioral and cognitive deficits 
when compared to adults. This is attributed to a population of activated or “primed” 
microglia that produce excessive amounts of pro-inflammatory cytokines, such as 
interleukin (IL)-6. The over production of IL-6 during aging is correlated with acute 
behavioral deficits in response to a peripheral infection or chronic behavioral deficits in 
the development of neurodegenerative diseases, such as Alzheimer’s and Multiple 
Sclerosis . However IL-6 is implicated in pro- and anti-inflammatory processes, so it is 
vital to understand it’s mechanisms in aging, neuroinflammation, and 
neurodegeneration.  
In initial studies using a microglia cell line (BV.2), we found that the IL-6 trans-
signaling pathway stimulated MHC-II, a marker of activation. While microglia isolated 
from aged IL-6 knock-out animals displayed significantly less MHC-II expression. 
Additionally, IL-6 knock-out animals were refractory to LPS-induced sickness behavior 
implicating the involvement of IL-6 and microglial activation in aging. However, which 
arm of IL-6 signaling had the most influential effects remained unclear. Recently, IL-6 
trans-signaling has been shown to induce the pro-inflammatory actions of IL-6 and 
selective blockade of the trans-signaling cascade using soluble gp130 (sgp130) has 
reduced the deleterious effects of peripheral inflammatory conditions such as Crohn’s 
disease and arthritis.  
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Although sgp130 has been shown to inhibit peripheral inflammation, its effects on 
the inflammatory response in the brain are unknown. If sgp130 reduces inflammation in 
the brain, it is rational to hypothesize that it will protect aged animals from infection-
related exaggerated levels of IL-6 and behavioral deficits. In a series of studies testing 
this hypothesis, sgp130 was found to inhibit LPS-induced IL-6 production via STAT3-
dependent action in BV.2 cells. In subsequent studies, adult and aged mice were co-
administered vehicle or sgp130 via intracerebroventricular (icv) and i.p. with saline or 
LPS. As expected, aged mice displayed deficits in locomotor activity and hippocampal-
dependent memory tasks, indicating they were more sensitive to peripheral immune 
stimulation. Importantly, LPS-induced sickness behavior and cognitive deficits in aged 
animals were mitigated by icv sgp130. These behavioral effects were mirrored by a 
reduction of STAT3 phosphorylation, IL-6 mRNA expression, and protein production in 
hippocampal tissue. Additionally, sgp130 also attenuated the induction of IL-6 protein 
from isolated microglia and astrocytes from the aged. These data show that inhibiting 
the IL-6 trans-signal, suggests a possible role in attenuating acute cognitive and 
behavioral disorders in older individuals with an infection. 
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Chapter 1 
General introduction and justification 
The average life expectancy in the United States has improved by almost 30 
years in the last half century, a trend which can be attributed to monumental 
advancements in modern medicine. These advances were vaccines and remedies to 
infectious diseases that predominately affected young children, providing them with 
sufficient immunity and the opportunity to survive until adulthood. These events have 
generated a population shift in society where there are an increased number of middle-
aged and advanced-aged individuals.  It is important to note that with this increase in 
aged individuals, a new set of diseases, where inflammation is a major pre-disposing 
factor have risen to prominence. 
Although vaccines were created to help our immune system mount a concerted 
response to infectious disease, the innate immune system has maintained its primal 
tenacity to respond to foreign agents and inflammation is a result. Inflammation is a 
response initiated by the innate immune system of an organism which releases 
inflammatory mediators in a protective attempt to remove injury, pathogens or stimulate 
healing. 
With the immune response unaltered in its reactivity to foreign invaders over 
time, an age-dependent upregulation of the inflammatory response due to chronic 
antigenic stress throughout life becomes apparent. The inflammatory response takes a 
toll on the human body and becomes the prevalent mechanism in age-associated 
disease (Candore et al., 2003; Licastro et al., 2005; Mariani et al., 2003; Vasto and 
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Caruso, 2005). Through an immune-to-brain axis, peripheral immune infection impairs 
cognition and reduces self-care behaviors in the aged contributing to a vicious cycle of 
higher hospitalization rates and a sizeable cost of healthcare supporting the aged. 
A significant contribution to the understanding of the aging phenotype is 
explained by the imbalance of inflammatory to anti-inflammatory networks, which results 
in a low-grade chronic pro-inflammatory state (Franceschi et al., 2000; Licastro et al., 
2005). Within this perspective, healthy aging and longevity are the result of not only a 
lower propensity to mount an effective inflammatory response, but also an inefficient 
anti-inflammatory network. Elucidating these mechanisms are essential to our 
understanding of aging.  
Interleukin (IL)-6 is a key molecule that has been implicated in pro- and anti- 
inflammatory action whose production increases in the body with age. IL-6 has been 
shown to be responsible for age-related alterations in peripheral and central nervous 
system (CNS) function, but the mechanism of pro- and anti-inflammatory actions have 
not been thoroughly examined. Studies have shown that high IL-6 levels in transgenic 
mice correspond to neurodegeneration and gliosis (Irizarry et al., 1997). Furthermore, 
IL-6 expression in the CNS has been shown to induce anorexia, inhibit long-term 
potentiation in hippocampal neurons, impair learning and memory, and induce 
hyperalgesisa (Bellinger et al., 1995; Dina et al., 2008; Papanicolaou et al., 1998).  
Therefore, it is hypothesized here that the neuro-pathological phenotype observed in 
the aging brain is influenced by the pro-inflammatory arm of IL-6. In this dissertation 
research, several behavioral, molecular, and genetic approaches were used to define 
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the signaling pathway involved in overexpression of pro-inflammatory mediated IL-6 in 
the brain of aged mice. The proceeding sections summarize peer-review literature 
concerning the properties, functions, and expression of IL-6, brain aging, and the role of 
IL-6 signaling in aging and neurodegeneration.  
 
1.1 Literature cited 
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Chapter 2 
Literature review 
2.1 History and general properties of interleukin-6 
Interleukin (IL)-6 is a pleiotropic cytokine that is implicated in a multitude of 
systems. Tadamitsu Kishimoto, a Japanese born immunologist has been credited with 
the critical research that was instrumental of our current understanding of the function 
and structure of IL-6 (Kishimoto, 2005). Various groups throughout the world from 
Kishimoto, Jacques Van Snick and Jack Gauldie, were studying what was presumed 
unrelated growth factors at the time, identified the myriad of actions of IL-6. These 
factors had many names and functions, interferon β2 (Weissenbach et al., 1980; 
Zilberstein et al., 1986), B-cell stimulatory factor (Hirano et al., 1985), hybridoma growth 
factor (Brakenhoff et al., 1987), hepatocyte-stimulatory factor (Gauldie et al., 1987), and 
cytotoxic T-cell differentiation factor (Takai et al., 1988), to name a few. It was not until 
1986 that human IL-6 was molecularly cloned, and a few years after that for the protein 
to be purified and utilized in studies to show that these seemingly different factors were 
the same molecule. 
 Interleukin-6 is a member of the long-chain class of four-α-helix bundle cytokine 
family. Human IL-6 is a single chain glycoprotein with a molecular weight ranging from 
21-30 kDa, while murine IL-6 is a 22-29 kDa protein (Nakajima et al., 1985; Simpson et 
al., 1988). The observed heterogeneity is due to extensive post-translational 
modification attributable to variations in glycosylation, phosphorylation at multiple serine 
residues, and sulfation, depending on the cellular source (May et al., 1991; Nakajima et 
al., 1985). The moderate differences of post-translational modification of IL-6 have little 
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to no effect on its biological activity, as evident by the identical nature of recombinant 
and natural IL-6. 
2.2 Immune-to-brain axis 
Until recently, the brain was believed to be an immunologically privileged site 
(Neuwelt and Clark, 1978), but there is now an appreciation that the peripheral immune 
system communicates with the brain. The group of Nance and Greenberg at the 
University of Manitoba were the first to demonstrate that peripheral immune stimulation 
directly activated nuclei in the brain (Wan et al., 1993). It is now a widely accepted 
notion that there is a bi-directional communication with the immune system and the 
brain. The brain responds to peripheral immune stimulus through multiple immune-to-
brain communication pathways to mount an appropriate immunological, physiological, 
and behavioral response that is an adaptive process (Dantzer et al., 1998a). Upon 
stimulation via an infectious pathogen, stress response, or injury, the peripheral innate 
immune system produces pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α 
via activated peripheral macrophages/monocytes (Gordon and Taylor, 2005), which act 
on the brain through neural, humoral and diffusive routes  (Dantzer et al., 2008).  
The neural pathway appears to be the main sensory pathway from abdominal 
organs to the brain and is primarily facilitated through vagal afferents, with input from 
other nerves in various sites where immunological processes occur (Goehler et al., 
2000). The projections from the vagus nerve enter the brain stem at the nucleus of the 
solitary tract (NTS), ascend to the parabrachial nucleus, and project to nuclei in the 
hypothalamus and other parts of the brain (Maier et al., 1998). Earlier studies showed 
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“proof-of-concept” that peripheral cytokines that signaled to the brain through vagal 
afferents were responsible for sickness behaviors by cutting the vagal nerve prior to 
stimulation by LPS or cytokines (Bluthe et al., 1996; Maier et al., 1998). Humoral routes 
revolve around the blood-brain-barrier (BBB), a structure consisting of capillary 
endothelial cells and astrocytes within the brain that physically separates circulating 
blood from brain parenchyma and cerebral spinal fluid (CSF) to prevent the diffusion of 
harmful molecules (Banks, 2006). Endothelial cells of the BBB have polarized sides that 
respond to circulating cytokines on their luminal side and secrete immune molecules of 
their own via their abluminal side directly into the brain (Verma et al., 2006). Cytokines 
are also actively transported across the BBB through a series of energy-dependent 
pumps and carrier-mediated system for cytokines (Banks, 2006). The diffusive route 
includes circumventricular organs (CVOs), sites of the brain that are devoid of an intact 
BBB. Here cytokines enter directly into the brain parenchyma via the blood by volume 
diffusion (Quan, 2008). Once the signal reaches the brain, these cytokines activate 
microglia cells, which propagate the signal throughout the CNS (Rivest, 2003). 
2.3 Brain immune activation 
The CNS is privy to its own immune system consisting of glial cells primarily 
microglia, the macrophage cells of the brain, that serve a dual role in neuromodulation 
and engagement in immunological processes (Kettenmann et al., 2011). The extent to 
which cytokines are involved in CNS homeostatic or disease processes is a delicate 
balance that relies on the remarkable ability for microglia to adapt to the input from the 
periphery. While activation of the peripheral and central innate immune system 
produces cytokines to control infection and repair injury, abnormal production can result 
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in a more severe or chronic neuroinflammatory state that has the potential to shift the 
microglia response from physiological to pathological (Kettenmann et al., 2011). 
Normally, microglia exist in a quiescent state in the healthy adult brain where 
they survey the microenvironment for changes and are characterized morphologically 
by a small soma and ramified processes for surveillance (Hanisch and Kettenmann, 
2007). Small changes in the CNS microenvironment (i.e. brain injury, infectious 
pathogen, and pH) trigger a rapid and transient activation of microglial cells with 
concomitant changes in morphology, metabolism, and phenotype. A key sign of 
microglia activation are the ramified processes seen at resting are shortened and the 
cell soma swells to an “amoeboid” state (Ransohoff and Perry, 2009). This change in 
morphology is accompanied by a heightened metabolism which corresponds to 
upregulated cell surface molecules, including major histocompatibility class (MHC)-II 
marker, receptors for cytokines and chemokines,  and several other cellular markers; as 
well as cytokine production, drastically changing the phenotype of the microglial cells  
(Perry, 1998).  
The pro-inflammatory cytokines released from activated microglia act on neurons 
to elicit a set of adaptive responses that affect physical (conductance) and behavioral 
outputs, which is intended to facilitate recovery from sickness (Kelley et al., 2003). This 
response is designed to be expedited and reversible, however evidence suggests that 
dysregulation of microglial cell activity may be responsible for a discordant central 
response to peripheral immune signals. Understanding individual cytokine involvement 
in microglia is a prime focus for therapeutic intervention across various 
neurodegenerative diseases and CNS insults.  
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2.4 Behavioral and cognitive changes 
 Various growth factors and cytokines are produced by activated microglia in 
response to peripheral or local stimulation. Pro-inflammatory cytokines target neurons 
and elicit a number of behavioral responses that are collective called “sickness 
behavior”. These behaviors include lethargy, reduced food intake, decreased social 
interaction, and general malaise (Hart, 1988). Sickness behavior is adaptive because it 
aids an animal in its recovery processes such as conservation of metabolic demand for 
clearance of pathogens from a disease or injury (Dantzer et al., 1998b). An example of 
this is the motivation of feeding in a sick animal is drastically reduced to increase 
restfulness, when compared to a healthy animal. This re-organization of behavioral 
priorities observed in animals with an acute infection exemplifies a necessity to alter 
behavior to benefit the animal under unfortunate circumstances. Pharmacological 
strategies where anti-inflammatory agents (i.e. IL-10, IL-1RA) were administered via 
peripheral or central routes to showed that individual cytokines are in fact involved in the 
onset or persistence of sickness behaviors (Bluthe et al., 1999; Kelley et al., 2003; Kent 
et al., 1992).  
 In addition to sickness behaviors, other neuronal output, such as cognitive 
dysfunction are associated with microglia activation and cytokine production (Graeber 
and Streit, 2010). Neuroanatomy must be taken into account, when considering 
cytokines’ effect on neurophysiology.  Consistent with the high density of microglia, 
cytokine concentrations are at their highest in the hippocampus, an area of the brain 
associated with learning and memory (Long et al., 1998; Schobitz et al., 1993). We 
understand that the hippocampus is involved in learning and memory from lesion 
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studies that show a severe impairment in cognitive processes (Chen et al., 1996), which 
agrees with electrophysiological data (D'Hooge and De Deyn, 2001). Further evidence 
that cytokines are crucial in altering neurophysiology is that elevated levels of IL-1β 
impedes performance of hippocampal-dependent learning and memory tasks such as 
contextual fear-conditioning and Morris water maze (Avital et al., 2003; Maier and 
Watkins, 1995).  
2.5 IL-6 in the CNS 
 The function of IL-6 within the CNS is complex; IL-6 exerts both neurotrophic and 
neuroprotective effects, as well as mediating inflammatory processes, gliosis, and 
demyelination within the cellular populations (Akira et al., 1993; Scheller and Rose-
John, 2006).  Studies have shown transcripts of IL-6 and IL-6 receptor (IL-6R) 
expressed in various regions of the brain, including the hippocampus, striatum, cortex, 
cerebellum, hypothalamus, and brain stem (Gadient and Otten, 1995; Schobitz et al., 
1993; Schobitz et al., 1992). Not only are IL-6 and IL-6R mRNAs expressed in different 
brain regions, they are co-localized on several neuronal types, indicating the breadth IL-
6’s actions throughout the CNS (Gadient and Otten, 1993; Schobitz et al., 1993).  
IL-6’s neurotrophic effects have been demonstrated in both in vitro and in vivo 
experiments. In vitro experiments have used the PC-12 neuronal cell line to show that 
IL-6 induces neurite outgrowth similar to nerve growth factor (NGF) (Marz et al., 1996), 
by blocking DNA fragmentation and preventing apoptosis (Kunioku et al., 2001; 
Umegaki et al., 1996). Similar results have been observed in primary neurons (Sarder et 
al., 1996). Additionally, IL-6 has been shown to protect various neuronal sub-
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populations from NMDA receptor activation induced-neurotoxicity (Liu et al., 2011). IL-6 
has also been implicated in neuroprotection against axotomy, ischemia, and nerve 
injury (Ikeda et al., 1996). However, with most things, spatial-temporal expression along 
with the amount of protein is important to the action of IL-6. Overproduction of IL-6 has 
been implicated in the enhanced intra-cellular calcium response to NMDA receptor-
activation neurotoxicity in cultured granule neurons (Nelson et al., 2002). IL-6 in the 
hippocampus has been shown to impair glutamate receptor expression, leading to 
impairments in synaptic plasticity and deficits in long-term potentiation (LTP) (Gruol and 
Nelson, 2005) 
While we know neurons respond to IL-6, major cellular contributors of IL-6 in the 
CNS are glial cells: astrocytes, microglia, and oligodendrocytes (Kishimoto, 2005; Taga 
and Kishimoto, 1997; Van Wagoner and Benveniste, 1999). Normally IL-6 is expressed 
at very low levels; however glial cell activation via overlapping stimuli purports the 
notion of the diverse functions of IL-6 and the tight cross communication between glial 
cells and neurons. These stimuli include brain injury (Gomes-Leal et al., 2004; Streit, 
1996), ischemic conditions such as in a stroke (Hughes et al., 2002), pro-inflammatory 
cytokines (e.g. IL-1β, IL-6, TNF-α, and IFN-γ) (Vitkovic et al., 2000), pathogen 
associated molecular patterns (PAMPs), various neurotransmitter and neuropeptides 
(e.g. acetylcholine and norepinephrine,) (Eulenburg and Gomeza, 2010), as well as 
disease associated peptides, such as β-amyloid plaques and S100β (Koenigsknecht-
Talboo and Landreth, 2005). Microglia primarily recognize all of the above stimuli, but 
evidence supports that they interact with astrocytes and astrocytes play a key role in 
neuroinflammation. Through loss of function studies, IL-6 is known to promote astrocyte 
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proliferation and astrocytes react with a delay, in contrast to microglia (Goswami et al., 
1998). 
2.6 The interleukin-6 receptor complex and recognition 
Interleukin-6 expression is modulated by IL-1β and TNF-α through an IL-6-
specific promoter region of nuclear factor kappa B (NF-κB) (NF-IL-6) (Akira et al., 1995). 
The role IL-6 has on its own regulation is extremely important when considering cellular 
sources and this has not been addressed in depth in the CNS. IL-6 exudes its biological 
effects on cells by binding its cognate receptor IL-6 receptor-α chain (IL-6R) and the 
recruitment of transmembrane signaling unit dimer glycoprotein 130 (gp130). The 
availability of the 3-dimensional structure of IL-6 has helped to construct a model of the 
IL-6 ligand interacting with the IL-6R and gp130, and give new insight into the process 
of molecular recognition and signaling. A 1.9A crystal structure of hIL-6 has been 
reported (Somers et al., 1997) and X-ray analysis reveals that 3-D structure of IL-6 is 
composed of a four helix bundle (Boulanger et al., 2003).  
Importantly, it is the IL-6R that maintains the affinity for IL-6 and once binding 
occurs, a conformation shift recruits gp130 subunits; it is gp130 that has the intracellular 
machinery to facilitate further signal transduction. The gp130 subunit is shared as a 
hetero- or homodimer amongst the IL-6 receptor family that includes IL-6, IL-11, ciliary 
neurotrophic factor (CNTF), leukemia inhibitory factor (LIF), and oncostatin M (OSM) 
(Kishimoto, 2005; Kishimoto et al., 1995). While expression of IL-6R is primarily on 
immune cells, gp130 is constitutively expressed across all cell types, which is consistent 
with the overlapping functionality of all the factors that use gp130 as a signaling subunit. 
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Identifying the site at which IL-6 binds/interacts with its receptor in addition to 
how the binding activates its receptor is critical to develop potential therapeutic 
strategies. Functional structure studies have identified three regions on the IL-6 
molecule that are important for binding to the IL-6R and gp130. There is a “site 1” on IL-
6 involved in binding to the IL-6R, which encompasses the C-terminal region of the ab-
loop/N-terminal part of helix B (Ehlers et al., 1994). An interesting finding was that IL-6 
does in fact associate with the gp130 subunit via site 1 interaction. Visualization of I125-
IL-6 to cellular membranes showed the association is only in the presence of IL-6R 
(Silvani et al., 1995). “Site II” on IL-6 is described as residues that are within helix A and 
C that also interact with gp130 (Paonessa et al., 1995). “Site III” is a second binding site 
for gp130 which comprises residues in the cd-loop/N-terminal end of helix D 
(Hammacher et al., 1994). A fourth binding site (“site 4”) determines the assembly of a 
functional hexameric 2:2:2 stoichiometry (IL-6, IL-6R, and gp130) of the IL-6 receptor 
complex (Boulanger et al., 2003; Ward et al., 1996) 
2.7 Interleukin-6 receptor and gp130 and signaling: classical vs. trans 
 The IL-6R is found in two forms, a membrane bound form which has a 
transmembrane spanning region and a soluble form that does not have a 
transmembrane spanning region. Experiments that molecularly cloned the IL-6R 
showed that the membrane bound form of IL-6R has a very short cytoplasmic region 
and is not essential for IL-6 signal transduction (Yamasaki et al., 1988). The soluble IL-
6R (sIL-6R) is strictly the extracellular region of the membrane bound form and is 
primarily generated by proteolytic shedding of membrane bound IL-6R by a class of 
enzymes TNF-α converting enzymes (TACE) or ADAM10/17 (Chalaris et al., 2010; 
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Franchimont et al., 2005; Mullberg et al., 1993); in certain cases sIL-6R is formed from 
an alternatively spliced mRNA species (Lust et al., 1995; Scheller and Rose-John, 
2006). Membrane bound IL-6 receptor is implicated in the classical signaling response 
and sIL-6R is implicated in the trans-signaling response. Binding affinity of IL-6 to sIL-
6R is very similar to membrane bound IL-6R (Muller-Newen et al., 1998; Schobitz et al., 
1995) and it is the act of binding that recruits gp130, the non-ligand-binding signaling 
transducing molecule. In classical signaling IL-6 binds directly to membrane bound IL-
6R and recruits gp130 signaling subunits; whereas trans-signaling involves the IL-6 
binding to sIL-6R in extracellular matrix to form an IL-6/sIL-6R complex that has a very 
high binding affinity for ubiquitously expressed gp130 signaling subunits. This trans-
signaling action confers IL-6 responsiveness to cells that do not typically respond to IL-
6. An age-old debate has been the pro- versus anti-inflammatory actions of IL-6 in the 
body (Gadient and Otten, 1997; Scheller et al., 2011). It appears as if the signaling 
mechanism plays an important part in mediating the actions of IL-6 and trans-signaling 
is heavily implicated in pro-inflammatory processes and disease models (Barkhausen et 
al., 2011; Greenhill et al., 2011; Mees et al., 2009; Nowell et al., 2009; Rabe et al., 
2008; Santer et al., 2010; Weidle et al., 2010). The principal idea of trans-signaling 
being a pro-inflammatory is the fact that cells which do not normally respond to IL-6, will 
recruit immune cells that respond to IL-6 to a site that was previously uninhabited with 
immune cells (Barrientos et al., 2011). 
sIL-6R and soluble gp130 (sgp130) have varying effects on circulating IL-6. 
While sIL-6R acts as a potent agonist, sgp130 acts as a partial antagonist, or decoy 
receptor, by binding the IL-6/sIL-6R complex and prevents the binding of membrane-
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bound gp130 and further signal transduction (Jostock et al., 2001). Under non-
pathological conditions, sIL-6R is present in moderate levels in plasma at ~25-35 ng/mL 
and in brain extracts at 300-900 pg/mL (Van Wagoner and Benveniste, 1999). The 
activity of the IL-6/sIL-6R complex is tightly controlled by molar excess of naturally 
occurring sgp130 present in serum at levels of 100-300ng/mL to competitively inhibit 
signaling via membrane-bound gp130 (Narazaki et al., 1993). 
The formation of the IL-6-IL-6R-gp130 complex is the initial step in IL-6 signaling. 
Upon hexameric complex formation, conformational changes lead to the dimerization of 
gp130 and intrinsic tyrosine kinases are autophosphorylated, resulting in the activation 
of Janus kinase-1 and 2 (Jak1 & Jak2). These tyrosine kinases phosphorylate the 
cytoplasmic region of gp130 creating recruitment sites for signal transducer and 
activation of transcription-3 (STAT3), a Src-homology-2 (SH2) domain-containing 
signaling molecule. Activated STAT3 forms a dimer, autophosphorylates, and 
translocates to the nucleus where it binds to inducing elements of the IL-6 promoter 
region. Thus the main consequence of classical IL-6 receptor action is to induce gene 
transcription and subsequent synthesis and secretion of IL-6 (Heinrich et al., 1998). 
Additionally, IL-6 activates the RAS/MAPK pathway through a gp130-associated SH2- 
containing protein phosphatase-2, as well as the phosphatidylinositol 3-kinase pathway 
which results in the transcription of IL-6 (Leonard et al., 1999).  
2.8 Interleukin-6 gene expression 
 Numerous cell types are capable of IL-6 gene expression and protein synthesis, 
due to classic and trans-signaling mechanisms and the relative potency of various 
stimuli to induce IL-6 production is cell-type dependent. It is necessary to understand 
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the gene structure and transcription machinery that are involved in expression patterns. 
Whether in humans or rodents, the IL-6 gene contains four introns and five exons and 
the position of intron/exon boundaries, exon length, and location of cysteine residues 
within the protein coding region are conserved across species (Tanabe et al., 1988). 
There are major similarities of gene organization in humans and rodents and a number 
of putative cis-acting elements that are required for inducible and tissue-specific 
transcriptional regulation located in the 5’ flanking region of the IL-6 gene (May et al., 
1991; Sehgal et al., 1986). While STAT3 is the major transcriptional regulator of IL-6, 
other response elements include a region that encompasses a multiple response 
element that has homology to c-fos serum response element (May et al., 1989), two 
CCAATT/enhancer binding protein (C/EBP) sites  NF-IL-6/IL-6DBP which are either 
mediated by STAT3 or CREB (Akira et al., 1992; Akira et al., 1990; Ramji et al., 1993), 
an AP-1 consensus site that corresponds with the MAPK pathway (Jang et al., 2008; 
Schuringa et al., 2001), and as stated above, a NF-κB site (Akira and Kishimoto, 1997).  
 The number of cell types that can express IL-6 translates to a wide range of 
stimulants that regulate the expression of IL-6. Activators span from physical injury, heat 
shock, other cytokines and growth factors, PAMPs, and environmental toxins (Scheller 
and Rose-John, 2006; Streit, 2000). In contrast, negative regulation of IL-6 transcription 
comes from suppressor of cytokine signaling (SOCS)-1 and 3. SOCS3 is a key 
physiological regulator of IL-6 signaling and was originally identified as a regulator of 
adaptive cytokine signaling pathways but has recently been shown to be important in 
regulating innate immune responses in macrophages (Croker et al., 2003; Niemand et 
al., 2003; Wang and Campbell, 2002). Cytokines such as IL-10, IL-4, IL-13, as well as  
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glucocorticoids are known to regulate IL-6 transcription (Heyen et al., 2000; Martinez et 
al., 2008).   
2.9 Brain aging 
 With advances in our understanding of immune-to-brain communications, it has 
become apparent that the immune system has an important role in regulating the 
progression of brain aging and major deleterious alterations in behavioral output, 
including an exaggeration of sickness behaviors, depression, and declines in cognitive 
performance. Moreover, changes in the CNS’s microenvironment during senescence, 
pre-disposes the aging brain to neurodegenerative diseases.  
It is important to note that healthy aged individuals have upregulated basal levels 
of pro-inflammatory cytokines, which has been suggested to create a permissive state 
for the on-set of neurodegenerative disease (Liu and Hong, 2003). The MacArthur 
foundation study on successful aging was a 20-year longitudinal study that revealed a 
correlation between mild cognitive impairments and elevated serum IL-6 (Weaver et al., 
2002). A similar study on patients with Alzheimer’s and Down’s syndrome showed that 
there is a clear correlation of heightened levels of IL-6, age, and neurodegenerative 
disease (Giunta et al., 2008; Warsch and Wright, 2010). 
A long-standing debate on the cause for cognitive decline seen in aging had two 
sides, one argument was that the decline was due to neuronal loss through death 
(Dayan, 1970), and the other believed it was due to a change in cell size (Terry et al., 
1987). While there is evidence to support both, new innovative experimental techniques, 
have improved our understanding of brain aging. A 1997 study in humans found a 
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steady decline in average brain weight starting after the age 60 (Mrak et al., 1997), 
while further studies showed a similar outcome of weight changes, with no significant 
variations in numbers of neurons in the brain of healthy aged individuals versus young 
individuals (Freeman et al., 2008). Rodent and non-human primate studies alike have 
provided further evidence that there is no global or hippocampal neuronal loss, and that 
there are stem cells that can proliferate and differentiate into neurons to replace lost 
neurons (Eriksson et al., 1998; Gazzaley et al., 1997; Rapp and Gallagher, 1996; Rapp 
et al., 1999). Although neuronal loss is not a significant factor in age-related processes, 
evidence from neurodevelopmental processes show that subtle changes in structure or 
microenvironment significantly affect neuronal populations, and changes in regions 
important for cognition may pre-dispose individuals to the onset of cognitive 
impairments (Casey et al., 2005; Dickstein et al., 2007).  
Aging appears to cause a shift in the cytokine-mediated sickness response from 
an adaptive to a maladaptive response, leading to behavioral complications (Dantzer et 
al., 1999; Wynne et al., 2009). Microglia serve as sensitive sensors of events occurring 
in their microenvironment, providing the first line of defense in the CNS (Block et al., 
2007). Activated microglia release immune mediators that coordinate the response of 
both innate and adaptive immunity to control infection, remove cell debris and promote 
repair (Kreutzberg, 1996).  An exaggerated or prolonged activation state has been 
observed in aging, which has detrimental effects (Block et al., 2007).  
The aged brain contains more reactive or hypersensitive microglia, which is 
denoted by markers of activation expressed on the surface such as CD68 and MHC-II. 
In animal models, a subset of microglia in reactive or ‘primed’ state constitute over 20% 
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of the population, when compared to 5% in adult animals (Henry et al., 2009). These 
primed microglia produce increased steady-state levels of cytokines, have begun their 
phenotypic shift towards the activated state, and have a higher cytokine secretion profile 
when further provoked (Combrinck et al., 2002; Deng et al., 2006; Sierra et al., 2007; Ye 
and Johnson, 1999b). For example, studies have shown that steady-state and LPS-
induced IL-6 production is increased in aged microglia (Ye and Johnson, 1999a). 
Astrocytes are derived from neuronal progenitor cells and have diverse functions, 
including providing structure and support to neurons, releasing neurotrophic factors, 
engaging in synaptic transmission, maintaining the integrity of the BBB, and interacting 
with microglia to improve the CNS microenvironment (Abbott et al., 2006; Pascual et al., 
2012). Astrogliosis or activation of astrocytes is another characteristic of age-related 
glial changes and Glial fibrillary acidic protein (GFAP), a major cytoskeletal protein of 
astrocytes, has been used as a marker to document age-related increases in the 
number of astrocytes in rodents and humans. It was found that GFAP protein and 
mRNA displayed an age-related increase in many areas of the brain, including 
hippocampus and cortex (O'Callaghan and Miller, 1991). Additionally, the neurotrophic 
cytokine S100β which is a marker of activated astrocytes is increased with age in 
human cortex (Sheng et al., 1996). The increase of GFAP and S100β expression is also 
consistent with anatomical studies that showed astrocyte hypertrophy with age (Griffin 
et al., 1995).  
Amplified or prolonged neuroinflammation leads to a maladaptive sickness 
response. Aged animals injected intraperitoneally with LPS exhibit protracted levels of 
IL-1β and IL-6 expression in the brain paralleled by prolonged deficits in food intake, 
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activity, and social behavior (Godbout et al., 2005). While it has been shown that 
peripheral factors negatively regulate neurogenesis and behavioral output in the aged 
(Villeda et al., 2011), the environment in the central compartment is paramount to 
behavioral output. ICV injection of LPS or gp120, a component of the AIDS virus cause 
prolonged sickness behavior in aged mice (Abraham et al., 2008; Huang et al., 2008). 
Infusing the receptor antagonist for IL-1β (IL-1RA) attenuated IL-1β gene expression 
and reversed the prolonged sickness behavior observed in aged animals (Abraham and 
Johnson, 2009), showing that there is a direct relationship between the central amplified 
cytokine response and exaggerated sickness behavior in the aged. 
Indeed in brain aging, there is a reduction in neuroprotective factors and an 
increase in inflammatory mediators. Neuronal populations are particularly vulnerable to 
both and age-related impairments in neuronal output and cognitive function are 
associated from these consequences. For example, in rodent models stimulating the 
peripheral immune system via LPS or live E.coli infection causes an amplified 
hippocampal cytokine response that corresponds to impaired hippocampal-dependent 
memory in spatial and contextual tasks in older animals (Barrientos et al., 2006; Chen et 
al., 2008). Potential mechanisms by which cytokines cause cognitive complications, 
include neuroinflammatory pathways augment neuronal physical properties and alter 
plasticity (i.e. neurogenesis and long-term potentiation (Griffin et al., 2006). In another 
example where neuroinflammation is prolonged similar to aging, IL-10 knock-out mice 
displayed hippocampal-dependent cognitive deficits and increased dendritic atrophy in 
the CA1 region of the hippocampus after LPS injection (Richwine et al., 2008). 
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However other mechanisms contribute to behavioral deficits seen in aging. 
Important to note, peripheral cells contribute to IL-6 levels in the CNS, from perivascular 
microglia, endothelial cells within the BBB, as well as infiltrating T-cells and 
macrophages (Iwasaki et al., 1999; Kaplanski et al., 2003; Romano et al., 1997; Simard 
and Rivest, 2004). In aging, the BBB remains intact, however it may be more 
susceptible to disruption as there is evidence of altered physio-chemical properties and 
functions of enzymes, receptors, and particular carrier transport systems, and adhesion 
molecules such as ICAM and VCAM are implicated (Miguel-Hidalgo et al., 2007; Shah 
and Mooradian, 1997).  
2.10 Aging, IL-6 and neurodegenerative diseases 
Glia cells are the most influential in producing neuroprotective factors and 
inflammatory mediators, and expression of such factors changes with aging and the 
occurrence of neurodegenerative diseases. Accumulating evidence from both animal 
and human studies has indicated that chronic inflammatory processes contribute to the 
pathogenesis of neurodegenerative diseases and IL-6 is one of the cytokines that is 
strongly correlated to the on-set and progression of disease. Depending on the disease, 
a potential mechanism of IL-6 is that it is a major inducer of acute-phase proteins (APP) 
and the presence of these proteins (i.e. α1-anti-chymotrypsin, α2-macroglobulin, and C 
- reactive protein (CRP) are involved in altering normal processing of amyloid precursor 
protein (APP) plaques and tangles in Alzheimer Disease patients, Lewy bodies in 
Parkinson’s, and mitochondrial dysfunction in Amyotrophic lateral sclerosis (Graeber 
and Streit, 2010; Hofmann et al., 2009; Rogers et al., 1996).    
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In transgenic mouse models, where mice overexpress APP, there is a state of 
gliosis, inflammation, and increased IL-6 production (Benzing et al., 1999). This 
activation of glial cells ultimately changes the microenvironment and leads to 
deleterious effects on neurons. Other transgenic mouse models that overexpress IL-6 in 
either astrocytes (Campbell et al., 1993) or neurons (Fattori et al., 1995) allowed 
researchers to directly investigate the neuroprotective or neuropathological effects of IL-
6 in the CNS. In mice where IL-6 is over-expressed in astrocytes, markers of astrocyte 
activation (i.e. S100β and GFAP) were upregulated, the BBB was disrupted, and other 
pro-inflammatory cytokines and APPs were increased (Campbell et al., 1993; 
Steffensen et al., 1994). These animals also had reduced LTP, structural changes in 
neurons within the hippocampus and cerebellum which directly corresponded to deficits 
in conditioned avoidance-learning (Bellinger et al., 1995; Campbell et al., 1993; Heyser 
et al., 1997). Interestingly, neuronal overexpressing (NSE-IL6) mice did not develop any 
of the neuronal manifestations, but developed active gliosis wherein astrocytes and 
microglia were recruited to neurons expressing IL-6 (Fattori et al., 1995). This action 
best describes the mechanism of the pro-inflammatory arm of IL-6 trans-signaling in the 
CNS. 
Locally, IL-6’s actions alone in the CNS are fairly weak; it is the presence of sIL-
6R that greatly enhances IL-6-mediated responses (Van Wagoner and Benveniste, 
1999). A model for multiple sclerosis that is pertinent to the pro-inflammatory IL-6 trans-
signaling arm is experimental autoimmune encephalitis (EAE). In the EAE mouse 
model, IL-6 is upregulated in cerebral spinal fluid, which is directly correlated with glial 
activation, breakdown of the BBB, and the infiltration of activated autoimmune T-cells. 
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IL-6 trans-signaling is known to mediate T-cell expansion, infiltration, and Thelper cell 
development (Diehl and Rincon, 2002; McLoughlin et al., 2005). Blockade of IL-6 trans-
signaling by injection of gp130-Fc fusion protein significantly delayed the onset of EAE 
in comparison to saline or isotype injected control animals. Histological evaluation 
revealed reduced numbers of infiltrated T-cells and macrophages in the spinal cord of 
gp130-Fc treated animals (Linker et al., 2008).  
Giuliani and colleagues observed significant increases of serum sIL-6R in 
humans throughout life, suggesting that trans-signaling plays a role in the upregulation 
of self-perpetuated IL-6 levels (Giuliani et al., 2001). However an important question 
remains: What role do microglia and astrocytes have on elevated levels of IL-6 in the 
brain? The dysregulation of trans-signaling leads to the lack of the resolution of 
inflammation and chronic inflammatory states, which subsequently results in the priming 
of immune cell types, destruction of affected tissues, and behavioral deficits. To this 
point, no studies have examined the modes of IL-6 receptor signaling in cells of the 
brain. Studies that evaluate the effects of blocking IL-6 trans-signaling in the aged and 
the extent to which neuroinflammation and behavior are affected will shed light on these 
actions. 
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Chapter 3 
Interleukin-6 is involved in microglia priming and the exaggerated LPS-induced 
sickness response in aged mice 
 
3.1 Abstract 
Interleukin (IL)-6 is increased in the brain of healthy aged animals and during 
peripheral infection, excessive production of pro-inflammatory cytokines in the aged 
brain from primed microglia induces behavioral pathologies. The pro-inflammatory 
cytokine IL-6 increases in the brain with age, but if it has a role in microglia priming is 
not known. The purpose of this study was to examine the functional role of IL-6 on 
microglia priming. In an initial study, BV.2 microglia were treated with soluble IL-6R (sIL-
6R) and IL-6 alone or in combination and MHC-II expression was assessed. While 
subsequent studies isolated microglia from adult (3-5 month) and aged (22-24 month) 
C57BL6/J (IL-6+/+) and IL-6 knock-out (IL-6-/-) mice showed significantly less MHC-II 
expression in aged IL-6-/- compared to IL-6+/+ counterparts. Additionally, adult and aged 
IL-6+/+ and IL-6-/- were injected with lipopolysaccharide (LPS) to simulate a peripheral 
infection and sickness behaviors (spontaneous locomotor behavior, body weight 
changes, and food intake) and hippocampal cytokine gene expression were measured 
over a 24 h period. Aged IL-6-/- animals were resilient to exaggerated LPS-induced 
reductions in locomotor behavior and changes in body weight. Additionally, the age-
associated baseline increase of IL-1β gene expression was ablated in aged IL-6-/- mice, 
suggesting IL-6 is a key driver of cytokine activity from primed microglia in the aged 
brain. Taken together, the present study suggests IL-6 expression throughout life is 
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involved in microglia priming and the increased amounts of IL-6 following peripheral 
LPS challenge is involved in the exaggerated and protracted sickness behavior 
response in the aged.  
3.2 Introduction 
Peripheral immune stimulation causes the production of pro-inflammatory 
cytokines, such as IL-6 and the signal for these cytokines are transported to the brain 
via neural and humoral pathways (Maier et al., 1998; Quan, 2008). In the brain, 
microglial cells react to the signal from the periphery and produce pro-inflammatory 
cytokines. These cytokines target neurons to elicit a sickness behavior response that is 
adaptive (Dantzer et al., 1998). Microglia appear to be the main cell in the brain that 
express the IL-6 receptor and potently secrete IL-6 during peripheral immune 
stimulation. IL-6-/-  animals have shown an overall decrease in the number of activated 
brain macrophages associated with lesions, suggesting a role for IL-6 in the 
orchestration of CNS inflammation (Penkowa et al., 1999). IL-6 production in the CNS is 
also implicated in a myriad of behavioral pathways (Banks et al., 1994; Campbell et al., 
1993; Vallieres et al., 1997). Recently we have shown that IL-6 in the brain plays a 
pivotal role in mediating lipopolysaccharide (LPS)-induced sickness behavior (Burton et 
al., 2011) as well as cognitive deficits (Sparkman et al., 2006) in adult animals.  
IL-6 is also upregulated in an array of neurodegenerative diseases (Gruol and 
Nelson, 1997; Licastro et al., 2003; Muller et al., 1998), indicating that IL-6 plays a 
crucial role as a mediator of processes in the central nervous system during disease 
and aging. 
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Microglia are derived from early myeloid lineage cells and represent 
approximately 10–12% of the total CNS cell population (Ginhoux et al., 2010). Normally, 
microglia are quiescent and in an immune surveillance state in the absence of any 
stimuli (Nimmerjahn et al., 2005). Once activated, microglia possess a macrophage-like 
phenotype including, inflammatory cytokine production, phagocytosis, and antigen 
presentation (Ransohoff and Perry, 2009). This neuroinflammatory process is normally 
transient with microglia returning to a resting state as the immune stimulus is resolved. 
However, in various brain environments from neurodegenerative disease to aging it is 
proposed that elements render microglia in a “primed” or “reactive” state, wherein a 
subsequent local or peripheral immune challenge causes an exaggerated and 
protracted cytokine production (Dilger and Johnson, 2008; Godbout and Johnson, 
2009).  
Markers of primed microglia such as major histocompatibility complex (MHC) 
classII (MHC-II) and CD68 are increased in the brain during normal aging (Frank et al., 
2006a; Ogura et al., 1994; Wong et al., 2005). Ex-vivo or peripheral immune stimulation 
results in an exaggerated cytokine response in microglia that express higher levels of 
MHC-II in aged animals (Henry et al., 2009; Njie et al., 2012). Furthermore, some 
studies support a link between IL-6 and MHC-II expression in monocyte-derived cells 
(Shafer et al., 2002; Vassiliadis and Papadopoulos, 1995). Evidence from previous 
studies in our lab show that microglia from aged animals are potent producers of IL-6 
(Godbout and Johnson, 2004; Ye and Johnson, 1999), and that decreasing the amount 
of IL-6 after or during peripheral stimulation decreases other pro-inflammatory cytokines 
as well as improves free radical production (Godbout et al., 2004). Further findings from 
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our and other labs show that exaggerated pro-inflammatory cytokines interact with the 
brain microenvironment  and exhibit more severe sickness behaviors (Godbout et al., 
2005), depressive-like behaviors (Godbout et al., 2008), and deficits in hippocampal-
dependent learning and memory compared with younger cohorts (Barrientos et al., 
2006; Chen et al., 2008). Interestingly, when the pro-inflammatory arm of IL-6 is 
inhibited during peripheral immune stimulation, aged animals are refractory to cognitive 
deficits (Burton and Johnson, 2011). Although these data lay the groundwork to support 
the notion that microglial priming plays a central role in exaggerated neuroinflammation 
and behavioral deficits, IL-6-specific involvement during aging has yet to be determined. 
3.3 Materials and methods 
BV.2 microglial cell culture 
The murine microglia cell line, BV.2 (a gift from Linda Van Eldik, Northwestern 
University, Evanston, IL) and have been used as a model to investigate the 
neuroimmune system (Jang et al., 2008; Zorina et al., 2010). Cells were maintained in 
150-cm2 tissue culture flasks (BD Falcon, Franklin Lakes, NJ) in DMEM (Bio-Whittaker, 
Cambrex, MD) supplemented with 10% FBS (Hyclone, Logan, UT),  200 mM glutamine, 
and 100 units/ml penicillin/streptomycin (Invitrogen, Carlsbad, CA) at 37°C in a 
humidified incubator under 5% CO2. Confluent cultures were passed by trypsinization. 
Cells were centrifuged (5 minutes (min) at 27°C, 200 × g), and culture medium was 
removed. In all experiments, cells were re-suspended in DMEM supplemented with 10% 
FBS and seeded in six-well plates (BD Falcon, Franklin Lakes,NJ) at a population of 5 × 
105 cells per well overnight at 37°C in a humidified incubator under 5% CO2 before 
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treatments. Cells were treated with sterile saline containing 0.1% BSA (vehicle) or sIL-
6R (R&D systems, Minneapolis, MN) for 1 hour (h) followed by treatment with 
recombinant IL-6 (R&D systems, Minneapolis, MN) for 24 h. Cells were then washed 
with ice cold PBS and prepared for flow cytometric analysis. BV.2 microglial cells were 
assayed for surface markers as described previously, with a few modifications (Burton 
et al., 2011). In brief, Fc receptors were blocked with anti-CD16/CD32 antibody 
(eBioscience, San Diego, CA) in a PBS-1% BSA/sodium azide solution, and incubated 
with anti-CD11b APC and anti- MHC-II PE (eBioscience, San Diego, CA), fluorescently 
labeled isotype antibodies for APC and PE (eBioscience, San Diego, CA), and 
unstained samples were used for controls. Expression of surface receptors was 
determined using a Becton-Dickinson LSR II Flow Cytometer (Red Oaks, CA). Thirty 
thousand events were collected and flow data were analyzed using FCS Express 
software (De Novo Software, Los Angeles, CA). 
Animal Studies 
Adult (3–5 months) and aged (22-24 months) male C57BL/6 (IL-6+/+ ) and IL-6 
knockout B6.129S2-Il6tm1 Kopf/J (IL-6-/-) (Kopf et al., 1994) mice were used. All mice 
were purchased from Jackson Laboratory (Bar Harbor, ME) and were 2-months old 
upon receipt.  Mice were housed in polypropylene cages and maintained at 21°C under 
a reverse-phase 12-h light-dark cycle with ad libitum access to water and rodent chow. 
At the end of each study, mice were examined post mortem for gross signs of disease 
(e.g., tumors or splenomegaly). Data from mice determined to be unhealthy were 
excluded from the analysis (<5%). All procedures were in accordance with the National 
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Institutes of Health Guidelines for the Care and Use of Laboratory Animals and were 
approved by the University of Illinois Institutional Animal Care and Use Committee. 
Experimental protocols 
Mice were handled 1-2 min each day for 7 days before experimentation to 
acclimate them to handling. In some cases microglia from whole brain was isolated from 
animals. To assess the effects of LPS on sickness behavior and pro-inflammatory gene 
expression in the hippocampus, mice were injected i.p. with sterile saline or 3.30 mg/kg 
BW (100 µg) LPS (serotype 0127:B8, obtained from Sigma, St. Louis, MO) and killed by 
CO2 asphyxiation 24 h later. Blood samples were collected via cardiac puncture into 
EDTA-coated syringes to obtain plasma, and the brain was rapidly removed and 
dissected to obtain hippocampal tissue. Hippocampal tissue was snap frozen in liquid 
nitrogen and stored at -80o C for later analysis. In some cases, mice were evaluated for 
sickness behavior before killed to obtain hippocampal tissue as described above.  
Microglia isolation 
In experiments for flow cytometry, microglia from whole brain were isolated as 
described previously, with few modifications (Cardona et al., 2006; Henry et al., 2009). 
Mice were euthanized by CO2 asphyxiation and whole brains were collected and stored 
in sterile PBS. Brains were homogenized by passage through a 70 µm cell strainer in 
Dulbecco’s Phosphate Buffered Salt Solution (DPBS) supplemented with 0.2% glucose. 
Resulting homogenates were centrifuged at 600 × g for 6 min at 10oC. Supernatants 
were removed and cell pellets were re-suspended in a 70% isotonic Percoll (GE-
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healthcare, Uppsala, Sweden) supplemented with phenol red (0.01%) at room 
temperature. A discontinuous Percoll density gradient of 70%, 50%, 35%, and 0% 
isotonic Percoll was set up. The gradient was centrifuged for 20 min at 2000 × g and 
microglia were collected from the interphase between the 70% and 50% Percoll layers 
(Frank et al., 2006b). Cells were washed with DPBS and then re-suspended in PBS- 
0.5% BSA/ 0.01% sodium azide solution (flow buffer). The number of viable cells was 
determined using a hemacytometer and 0.1% trypan blue staining; each isolation 
yielded approximately 3 ×105 viable cells. 
Flow Cytometry 
Flow cytometric analysis of microglial surface markers was performed as 
described previously, with a few modifications (Henry et al., 2008). In brief, Fc receptors 
were blocked with anti-CD16/CD32 antibody (eBioscience, San Diego, CA) in flow 
buffer. The cells were then incubated with anti-CD11b-Allophycocyanin (APC), anti-
CD45-Fluorescein isothiocyanate (FITC), and anti-MHC-II-Phychoerythrin (PE) 
antibodies (eBioscience, CA); fluorescently labeled isotype antibodies for APC, FITC, 
and PE (eBioscience, San Diego, CA), and unstained samples were used as controls. 
Expression of surface receptors was determined using a Becton-Dickinson LSR II Flow 
Cytometer (Red Oaks, CA). Thirty thousand events were collected and microglia were 
identified by CD11b+ and CD45+low expression (Ford et al., 1995). Flow data were 
analyzed using FCS Express software (De Novo Software, Los Angeles, CA).  
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Behavioral tests 
Locomotor activity: Mice were maintained in their home cage and locomotor 
activity was video recorded during 5 min intervals using a camera mounted 
approximately 91.0 cm directly above the center of the cage floor. Tests were 
conducted during the dark phase (between 07:00 and 19:00) of the light/dark cycle 
under infrared lighting to aid video recording. Baseline behavior was taken just before 
LPS treatment (0 µg or 100 µg i.p.) and 4, 6, 8, and 24 h afterwards.  Videos were 
tracked to by Ethovision (Noldus, Leesburg, VA) software, to record total distance 
moved. Body weight and food intake were measured at each time point over the 24 h 
period.  
Cytokine mRNA measurement by quantitative real-time PCR 
Total RNA from hippocampus was isolated using the Tri Reagent protocol 
(Sigma, St. Louis, MO.) A QuantiTect Reverse Transcription Kit (Qiagen, Valencia, CA) 
was used for cDNA synthesis with integrated removal of genomic DNA contamination 
according to the manufacturer’s protocol. Quantitative real time PCR was performed 
using the Applied Biosystems (Foster, CA) Assay-on Demand Gene Expression 
protocol as previously described (Krzyszton et al., 2008). In brief, cDNA was amplified 
by PCR where a target cDNA (IL-6, Mm00446190_m1; IL-1β, Mm00434228_m1; TNF-
α, Mm00443258_m1; and CD68, Mm0089636_g1; MHC-II, Mm00439221_m1) and a 
reference cDNA (glucose-3 phosphate dehydrogenase, Mm99999915_g1) were 
amplified simultaneously using an oligonucleotide probe with a 5’ fluorescent reporter 
dye (6-FAM) and a 3’ quencher dye (NFQ). PCR reactions were performed in triplicate 
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under the following conditions: 50oC for 2 min, 95oC for 10 min, followed by 40 cycles of 
95oC for 15 sec and 60oC for 1 min. Fluorescence was determined on an ABI PRISM 
7900HT-sequence detection system (Perkin Elmer, Forest City, CA). Data were 
analyzed using the comparative threshold cycle (Ct) method, and results are expressed 
as fold difference. 
Statistical analysis 
All data were analyzed using the ANOVA routine in Statview and MIXED 
procedure of the Statistical Analysis System software (SAS Inst., Cary, NC). Data were 
subjected to a univariate analysis to ensure normality. BV.2 average data was subjected 
to a two-way ANOVA (pre-treatment × treatment).  Locomotor data were and subjected 
to an ANOVA (age × genotype × treatment × time) using repeated measures in which 
time (0, 4, 6, 8, and 24 h) was a within subjects measure, and age and treatment (LPS 
or sterile saline) and genotype were between subjects measures, but data split into 
genotype graphs for ease of reading. Weight loss, food intake, microglia, and cytokine 
mRNA data were analyzed using a three-way ANOVA (age × genotype × treatment).  
Post hoc Student’s t test of least square means was used to determine if treatment 
means were significantly different from one another (p<0.05). All data are presented as 
mean ± standard error of the mean (SEM). 
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3.4 Results 
IL-6- trans-signaling induced MHC-II expression in BV.2 microglia 
To assess if IL-6 signaling is involved in MHC-II induction on microglial cells, 
MHC-II cell surface expression was examined after cells were pre-treated 1 h with 
vehicle or sIL-6R then treated 24 h with 0, 100, or 1000 pg/mL IL-6. Figures 3.1, 3.2, 
and 3.3 show two-color dot blots, while Figure 3.4 is a bar graph that summarizes the 
data of average expression of MHC-II. Previous studies have shown IL-6 alone has an 
effect on MHC-II expression (Shafer et al., 2002), but recent studies implicate IL-6 
trans-signaling in pro-inflammatory processes (Greenhill et al., 2011), and we believe 
this to be important in microglia activation. Figures 3.1A and B display that vehicle and 
sIL-6R treated microglial BV.2 cells express a similar amount of MHC-II, roughly 50% of 
the cells. Figure 3.2 demonstrates that treatment with 100 pg/mL IL-6 alone does not 
significantly induce MHC-II expression (Figure 3.2A). However pre-treatment with sIL-
6R for 1 h significantly increased the induction of MHC-II expressing cells to 100 pg/mL 
IL-6 (p<0.01) (Figure 3.2B), this data displays that the IL-6 trans-signaling pathway is in 
fact implicated in activating microglia cells. Figure 3.3 indicates a ceiling effect, whereby 
1000 pg/mL of IL-6 in the absence or presence of sIL-6R maximally induces MHC-II 
expression on microglia cells at 80-90% of the cells. These findings suggest that classic 
and trans-signaling on microglia readily regulate microglia activation or priming.  
Microglia from aged IL-6-/- animals are refractory to priming 
In aging, there is a population of microglia that are in a primed state, and MHC-II 
is a marker of this. Studies have found that mRNA and protein for MHC-II is basally 
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upregulated during aging (Frank et al., 2006a; Henry et al., 2009), and may be a major 
pre-disposing factor for the exaggerated pro-inflammatory cytokine production seen in 
aging (Henry et al., 2009). Therefore, we investigated the effects of IL-6 throughout life 
by isolating microglia from adult and aged IL-6+/+ and IL-6-/- mice, stained for CD11b, 
CD45, and MHC-II, and analyzed them by flow cytometry (Figures 3.5, 3.6, and 3.7). To 
verify our microglia population, we profiled the isolated cells for a CD11b+/CD45low cell 
population in representative two-color dot blots for adult (Figure 3.5A) and aged (Figure 
3.6A) animals (Ford et al., 1995). Upon identifying microglia cells, we then gated our 
population for CD11b+/MHC-II+ for each age and genotype (Figures 3.5B and C and 
3.6B and C). Despite the strain difference from previous studies (BALB/c vs. C57 B/6) 
(Henry et al., 2009) the results are consistent in that, the number of MHC-II expressing 
microglia is increased in IL-6+/+ aged individuals to about 20% versus 4% in adult 
animals (Figure 3.7). Interestingly, the microglia from aged IL-6-/- animals displayed a 
significantly reduced number of MHC-II expressing microglia, down to roughly 11% 
(p<0.05) (Figure 3.6C). While there was no difference in MHC-II expression in IL-6-/- 
versus IL-6+/+ adult animals (Figures 3.5B and C). 
IL-6 is involved in recovery from LPS-induced sickness behavior in aged animals 
Primed microglia produce exaggerated amounts of pro-inflammatory cytokines, 
including IL-6 that induces exacerbated and prolonged sickness behaviors. Given the 
results from our and others’ studies (Burton et al., 2011; Nguyen et al., 2011); we 
investigated the effects of IL-6 and LPS-induced sickness behaviors in the aged. Adult 
and aged IL-6+/+ and IL-6-/- animals were administered LPS i.p. and locomotor activity 
(Figures 3.8 and 3.9), body weight, and food intake (Figures 3.10 and 3.11) were used 
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as measures of sickness. As expected, LPS-treated IL-6+/+ adult and aged animals 
showed a time-dependent decrease in locomotor activity (p<0.001). Adult and aged IL-
6-/- animals also displayed a decrease in locomotor activity for the 4 and 6 time points 
(Figures 3.8 and 3.9). In Figure 3.8, LPS induced modest sickness in adult IL-6+/+ mice 
where LPS-induced sickness behavior returned to baseline by 24 h post-injection, 
however, aged IL-6+/+ mice were still impaired at 24 h, consistent with prior studies 
(Godbout et al., 2005). The LPS-induced depression of locomotor activity in IL-6+/+ adult 
and aged mice was ameliorated in the IL-6-/- animals at the 8 h time point, an moderate 
difference in the adult, and a dramatic improvement in the aged (Figure 3.9). LPS-
treated IL-6-/- aged animals were statistically lower from saline-treated animals at the 4 
and 6 h time point, however the depression was not as severe as IL-6+/+ counterparts. 
The initial depression of locomotor activity can be attributed to LPS-induced IL-1β 
production, which is implicated in the onset of sickness (Abraham and Johnson, 2009). 
The LPS-induced sickness response was not inhibited in adult IL-6-/- animals as well, 
however these animals exhibited a similar recovery to LPS treatment at 8 h post LPS 
similar to the aged animals. Additionally, IL-6 had significant mitigating effects on LPS-
induced weight loss (p<0.05, Figure 3.10B) in aged animals, where the weight loss was 
not exaggerated as in the IL-6+/+ animals. However the lack of IL-6 did not have similar 
effects in adult animals. Moreover, LPS-induced reductions in food intake for both IL-6+/+ 
and IL-6-/- aged animals were significantly lower than LPS-treated adult counterparts 
(Figures 3.11A and 3.11B). Similar to the weight loss data the food intake data showed 
no difference in adult IL-6-/- animals. These data suggest that IL-6 is important for 
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maintaining sickness behavior and aged animals appear to be more sensitive to the 
effects of LPS-induced IL-6 production. 
IL-6 is implicated in reduced levels of baseline IL-1β and MHC-II gene expression 
in aged animals 
Previous studies have shown that MHC-II activated microglia are mainly 
responsible for the exaggerated production of IL-1β (Henry et al., 2009), and our earlier 
results suggest that a life devoid of IL-6 reduces the amount MHC-II expressed on 
microglia. We then proposed to assay for gene expression of markers of inflammation 
IL-1β, TNF-α, MHC-II, CD68, and IL-6 in hippocampal tissue 24 h after LPS treatment. 
We chose to use the hippocampus, because it is enriched in microglia and a region of 
the brain that is sensitive to LPS-induced pro-inflammatory cytokines. Our data is 
consistent with previous studies (Godbout et al., 2005) and shows a basal age-related 
upregulation of IL-1β, IL-6, and MHC-II expression seen in IL-6+/+ animals, however in 
IL-6-/- animals, this upregulation is significantly decreased in IL-1β (Figure 3.12A) and 
MHC-II (Figure 3.12C). Upon LPS treatment there was no significant overall age × 
genotype × LPS interaction in IL-1β, TNF-α, MHC-II, or CD68 gene expression. This 
signifies that, while IL-6 is not the only cytokine important for microglia priming and 
exaggerated cytokine production, it is an integral component. 
3.5 Discussion 
Peripheral immune-to-brain communication causes the upregulation of various 
pro-inflammatory cytokines, including IL-6. During normal aging, primed microglia are 
responsible for the exaggerated and prolonged cytokine production and the ensuing 
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behavioral response during a peripheral infection (Godbout et al., 2005; Godbout and 
Johnson, 2009); making it a necessity to understand the involvement of individual 
cytokines on microglial priming and behavioral output, during aging.  These data extend 
ours’ and others’ previous works, with several novel findings. First, we show that IL-6 
trans-signaling is an important pathway for MHC-II induction (Figure 3.4). Secondly, the 
age-related increase of MHC-II expression was decreased in aged IL-6-/- microglia 
(Figure 3.7). Next, we showed the exaggerated sickness behavior response seen in 
aged animals after peripheral LPS injection was mitigated in the IL-6-/- animals (Figures 
3.8, 3.9, 3.10B). Lastly, baseline age-related induction of IL-1β and MHC-II was 
decreased in aged IL-6-/- mice (Figures 3.12A and C). These data further demonstrate 
that MHC-II plays a role in microglial hyperactivity in the aged brain and indicate that IL-
6 is a significant contributor to the microglia-induced exaggeration in neuroinflammation 
in aged mice following peripheral immune stimulation. 
An important finding of this study was the age-related increase of MHC-II 
expression in microglia and hippocampal tissue was down-regulated in aged IL-6-/- 
animals (Figures 3.6 and 3.12C). We and other labs have previously reported an age-
related increase in MHC-II gene expression in the brain of aged animals (Frank et al., 
2006a; Godbout et al., 2005), but the current study provides novel evidence of an IL-6 
dependent mechanism for increased MHC-II mRNA in hippocampus and protein 
expression on microglia isolated from aged mice. The data shows, approximately 20% 
of microglia from aged IL-6+/+ mice were positive for MHC-II expression compared to 
11% in the aged IL-6-/- animals (Figure 3.7) and the hippocampal tissue displayed half of 
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the baseline gene expression seen in aging (Figure 3.12C). These data indicate that IL-
6 is involved in the primed phenotype in microglia from aged mice. 
Microglia priming is implicated in various other models of peripheral stimulation. 
For instance, in the ME7 murine model of prion disease, peripheral administration of 
LPS induces an upregulated pro-inflammatory cytokine response in microglia, which 
elicits exaggerated sickness behavior, and accelerates progression of the disease 
(Combrinck et al., 2002; Cunningham et al., 2009). Similar studies in other rodent 
models of chronic neurodegenerative disease, such as amyotrophic lateral sclerosis 
(Nguyen et al., 2004; Nguyen et al., 2002), show the disease is responsible for a 
priming effect and a subsequent signal from the periphery elicits a microglial response 
that is greater in magnitude than individual stimuli alone. This interaction lays the basis 
to our understanding on how infection serves as a risk factor for exaggerated behavioral 
manifestations in patients with chronic neurodegenerative diseases such as multiple 
sclerosis and Alzheimer’s disease (Dilger and Johnson, 2008; Holmes et al., 2003).  
A recent study using IL-6 knock-out animals showed that IL-6 is important for 
peripheral immune stimulated- sickness behavior in adult animals (Nguyen et al., 2011), 
while other studies that block the pro-inflammatory arm of IL-6 signaling facilitated 
recovery of LPS-induced sickness behavior in adult animals (Burton et al., 2011). A 
complementing finding of this study was that the aged IL-6-/- animals’ sickness behavior 
response to peripheral LPS injection was blunted. Based on previous findings in older 
mice (Godbout et al., 2005), we anticipated that LPS injection would be associated with 
a protracted decrease in locomotor activity and an exaggeration in weight loss and a 
decrease in food intake over a 24 h period. As expected, there was a significant 
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decrease in locomotor activity in LPS treated aged IL-6+/+ mice, (Figure 3.8), body 
weight (Figure 3.10A), and food intake (Figure 3.11A) 24 h after injection. Interestingly, 
both adult and aged IL-6-/- animals displayed a recovery from LPS-induced depression 
of locomotor activity at 8 h post LPS (Figure 3.9), a significant improvement. Body 
weight measurements 24 h after LPS injection showed that the aged IL-6-/- response 
was no different than the adult LPS treated groups, demonstrating that aged IL-6-/-  
animals do not show the exaggerated behavioral phenotype (Figure 3.10B). Contrary to 
our expectations, food intake from aged IL-6-/- animals was significantly decreased 
(Figure 3.11B); presumably because IL-1β compensates for IL-6 to act in the 
hypothalamus to control food intake (Harden et al., 2008). Further evidence of IL-6 as a 
neuromodulator have been shown in studies where adult IL-6-/- animals were refractory 
to LPS-induced deficits in the Morris water maze, while other studies from our lab have 
shown that blocking the pro-inflammatory arm of IL-6 in aged animals, rescued LPS-
induced deficits in hippocampal-dependent contextual fear conditioning (Burton and 
Johnson, 2011).  
A final original finding was that, baseline upregulation of gene expression of IL-1β 
and MHC-II observed in aging was decreased in the hippocampus of IL-6-/- aged 
animals (Figure 3.12A and C). In aging, primed microglia exhibit constitutive expression 
of IL-1β (Henry et al., 2009), and this is associated with neurological disease (Griffin 
and Mrak, 2002) and behavioral deficits (Abraham and Johnson, 2009). This 
downregulation displays a possible new mechanism of IL-6 - IL-1β interaction, where 
other studies have shown that IL-1β influences IL-6 (Cahill and Rogers, 2008), but this 
data provides evidence of a bi-directional interaction. Taken together, our findings 
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indicate that IL-6 is involved in microglial priming and the immunological and behavioral 
deficits seen after peripheral LPS challenge in the aged. 
In conclusion, the present study demonstrates that IL-6 is involved in the 
pronounced age-related increase in MHC II protein in microglia. Moreover, IL-6 
augments the behavioral response to peripheral LPS injection associated with 
exaggerated microglial activation, and induction of pro- inflammatory IL-1β in aging. 
These data are significant because they show the importance of IL-6 to microglial 
priming in the aged brain, and provides further evidence that MHC II activated microglia 
are significant contributors to the exaggerated neuroinflammation and behavior in aged 
mice following peripheral LPS challenge. 
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3.6 Figures 
 
Figure 3.1: Differential expression of IL-6-induced MHC-II on microglia. 
Representative two-color dot plot; cells were treated 24 h with vehicle or sIL-6R and  incubated 
with anti-CD11b APC and anti-MHC-II PE and expression of the cell surface markers was 
assessed; compared with isotype and unstained controls. 
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Figure 3.2: Higher expression of IL-6-induced MHC-II on microglia in the presence 
of sIL-6R. Representative two-color dot plot; cells were pre-treated 1 h with vehicle or sIL-6R 
then treated 24 h with 100 pg/mL IL-6 then and incubated with anti-CD11b APC and anti-MHC-II 
PE and expression of the cell surface markers were assessed; compared with isotype and 
unstained controls. 
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Figure 3.3: Maximal expression of IL-6-induced MHC-II on microglia. Representative 
two-color dot plot; cells were pre-treated 1 h with vehicle or sIL-6R then treated 24 h with 1000 
pg/mL IL-6 then and incubated with anti-CD11b APC and anti-MHC-II PE and expression of the 
cell surface markers were assessed; compared with isotype and unstained controls. 
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Figure 3.4: Differential expression of IL-6-induced MHC-II on microglia. Average 
percentage of cells that were pre-treated 1 h with vehicle or sIL-6R then treated 24 h with 100 or 
1000 pg/mL IL-6. Cell surface markers were assessed for MHC-II expression; compared with 
isotype and unstained controls. Bars represent the mean ± SEM. Results are an average of 3 
independent experiments. Means with different letters are significantly different from one 
another (P<0.05). 
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Figure 3.5: Expression of microglial MHC-II on adult IL-6+/+ and IL-6-/- animals. 
Representative two-color dot plot of percoll-isolated cells stained with anti-CD11b APC and anti-
CD45 PE; identified by CD11b+/CD45low staining.  Identified microglia were gated by 
CD11b/MHC-II positivity; expression of the cell surface markers were assessed and compared 
with isotype and unstained controls. 
 
 
 
 
 
IL-6+/+ IL-6-/- 
A. 
B. 
C. 
Adult 
64 
 
 
 
Figure 3.6: A reduction of microglial MHC-II on aged IL-6-/- compared to IL-6+/+ 
animals. Representative two-color dot plot of percoll-isolated cells stained with anti-CD11b APC 
and anti-CD45 PE; identified by CD11b+/CD45low staining.  Identified microglia were gated by 
CD11b/MHC-II positivity; expression of the cell surface markers were assessed and compared 
with isotype and unstained controls. 
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Figure 3.7: Differential expression of MHC-II on adult and aged IL-6+/+ and IL-6-/- 
microglia. Average percentage of cells that were CD11b+/MHC II. Cell surface markers were 
assessed for MHC-II expression; compared with isotype and unstained controls. Bars represent 
the means ± SEM (n = 6). Means marked with a * are significantly different from age-matched 
control (P < 0.05). 
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Figure 3.8: LPS-induced sickness behavior in adult and aged adult IL-6+/+ animals. Mice 
were injected i.p. with sterile saline or LPS (100 µg). Spontaneous locomotor baseline behavior 
was measured before LPS injection (0) and at 4, 6, 8, and 24 h post-injection. Bars represent 
the mean ± SEM (n = 8-9) Means with * are statistically different (P<0.05) from saline controls. 
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Figure 3.9: Adult and aged IL-6-/- mice recover more quickly from LPS-induced sickness 
behavior. Mice were injected i.p. with sterile saline or LPS (100 µg). Spontaneous locomotor 
baseline behavior was measured before LPS injection and at 4, 6, 8, and 24 h post-injection. 
Bars represent the mean ± SEM (n = 8-9) Means with * are statistically different (P<0.05) from 
saline controls. 
 
 
 
 
 
IL-6-/- 
68 
 
 
Figure 3.10: LPS-induced sickness behavior in adult and aged adult in IL-6+/+ and IL-6-/- 
animals. Mice were injected i.p. with sterile saline or LPS (100 µg). Body weight was measured 
before LPS injection and at 24 h post-injection. Bars represent the mean ± SEM (n = 8-9) 
Means with different letters are statistically different (P<0.05) from saline controls. 
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Figure 3.11: LPS-induced sickness behavior in adult and aged adult IL-6+/+ and IL-6-/- 
animals. Mice were injected i.p. with sterile saline or LPS (100 µg). Food intake was measured 
before LPS injection and at 24 h post-injection. Bars represent the mean ± SEM (n = 8-9) 
Means with different letters are statistically different (P<0.05) from saline controls. 
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Figure 3.12: LPS-induced IL-6+/+ and IL-6-/- gene expression. Hippocampal tissue was 
collected 24 h after i.p. LPS (100 µg) and assayed for IL-1β, TNF-α, MHC-II, CD68, and IL-6. 
Aged IL-6-/- animals had reduced baseline levels of IL-1β and MHC-II expression. Bars 
represent the mean ± SEM (n = 8-9) Means with different letters are statistically different from 
each other (P<0.05). 
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Chapter 4 
Inhibition of interleukin-6 trans-signaling in the brain facilitates recovery from 
lipopolysaccharide-induced sickness behavior 
 
4.1 Abstract  
Interleukin (IL)-6 is produced in the brain during peripheral infection and plays an 
important but poorly understood role in sickness behavior. Therefore, this study 
investigated the capacity of soluble gp130 (sgp130), a natural inhibitor of the IL-6 trans-
signaling pathway to regulate IL-6 production in microglia and neurons in vitro and its 
effects on lipopolysaccharide (LPS)-induced sickness behavior in vivo. Murine microglia 
(BV.2) and neuronal cell lines (Neuro.2A) were used to study the effects of stimulating 
and inhibiting the IL-6 signaling pathway in vitro. In vivo, adult (3-6mo) BALB/c mice 
received an intracerebroventricular (icv) injection of sgp130 followed by an 
intraperitoneal (i.p.) injection of LPS, and sickness behavior and markers of 
neuroinflammation were measured. Soluble gp130 attenuated IL-6- and LPS-stimulated 
IL-6 receptor (IL-6R) activation along with IL-6 protein release in both microglial (BV.2) 
and neuronal (Neuro.2A) cell types in vitro. Moreover, in vivo experiments showed that 
sgp130 facilitated recovery from LPS-induced sickness, and this sgp130-associated 
recovery was paralleled by reduced IL-6 receptor signaling, mRNA, and protein levels of 
IL-6 in the hippocampus. Taken together, the results show that sgp130 may exert an 
anti-inflammatory effect on microglia and neurons by inhibiting IL-6 binding. These data 
indicate that sgp130 inhibits the LPS-induced IL-6 trans-signal and show IL-6 and its 
receptor are involved in maintaining sickness behavior. 
  
78 
 
4.2 Introduction 
Peripheral infection stimulates production of pro-inflammatory cytokines including 
interleukin (IL)-1β, IL-6, and tumor necrosis factor-α (TNF-α). These cytokines use 
neural and humoral pathways to convey a message to the brain (Maier et al., 1998; 
Quan, 2008). In the brain, the peripheral pro-inflammatory signal is mimicked by 
microglia, (Ransohoff and Perry, 2009) and the resulting cytokines target neurons to 
elicit sickness- related behaviors that are typically adaptive (Kelley et al., 2003). 
However, excessive cytokine production by microglia is associated with prolonged 
sickness behavior (Abraham and Johnson, 2009a; Combrinck et al., 2002; Godbout et 
al., 2005b; Huang et al., 2008), cognitive deficits (Campbell et al., 1993; Chen et al., 
2008; Heyser et al., 1997), and affective disorders like anxiety and depression (Mines et 
al., 2010; Sparkman and Johnson, 2008). A recent study showed IL-6 knockout mice 
were refractory to LPS-induced increases of cytokines in the brain and cognitive deficits 
eluding to the potential permissive effects of IL-6 during LPS-induced sickness 
(Sparkman et al., 2006). 
The IL-6 receptor is activated through two separate, but related pathways; 
classical- and trans-signaling. Classical IL-6 receptor activation is facilitated through the 
IL-6 ligand binding to its membrane-bound receptor. The receptor consists of two 
subunits: the IL-6 receptor-alpha chain (IL-6R), which binds IL-6, and the trans-
membrane signaling subunit, glycoprotein 130 (gp130), which is the intra-cellular signal 
trans-ducer and is ubiquitously expressed.  Both IL-6R and gp130 are cleaved 
immediately before the membrane spanning region by alternative splicing or shed by 
proteolytic enzymes to produce a soluble receptor located in extra-cellular matrix. It is 
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important to note that the expression pattern of IL-6R is limited to few cells of the 
immune system and conservatively dispersed among other cell types, meaning classical 
signaling is highly conserved. In contrast, gp130 is ubiquitously expressed (Heinrich et 
al., 1998; Kishimoto et al., 1992). The basis of trans-signaling is soluble IL-6R (sIL-6R) 
binding to IL-6 in the extra cellular matrix to form a IL-6/sIL-6R complex, which has an 
increased binding affinity to membrane-bound gp130 subunits, resulting in the capability 
of IL-6 production in any cell type that expresses gp130 (Jones et al., 2005; Rosejohn 
and Heinrich, 1994). 
Upon binding through either the classical or trans-signal, gp130 dimerizes and 
autophosphorylates, resulting in the activation of Janus kinase-1 and 2 (Jak1 & Jak2). 
These tyrosine kinases phosphorylate the cytoplasmic region of gp130 creating 
recruitment sites for signal transducer and activation of transcription-3 (STAT3), a Src-
homology-2 (SH2) domain-containing signaling molecule. Activated STAT3 forms a 
dimer, autophosphorylates, and translocates to the nucleus where it binds to enhancer 
elements of the IL-6 promoter region. Thus the main consequence of both classical or 
trans-signal IL-6 receptor action is to induce gene transcription and subsequent 
synthesis and secretion of IL-6, though trans-signaling allows this in many more cell 
types, due to the ubiquitous expression of gp130 (Heinrich et al., 1998). sIL-6R and 
soluble gp130 (sgp130) have varying effects on circulating IL-6. Where sIL-6R acts as 
an agonist, sgp130 acts as a partial antagonist, or decoy receptor, by binding IL-6 or the 
IL-6/sIL-6R complex and prevents the binding of membrane-bound gp130 and further 
signal transduction (Jostock et al., 2001).  
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The action of IL-6 is heavily dependent on the location of the receptors and the 
cell types exposed to the cytokine. For instance, IL-6 binding to IL-6R located on T-cells 
leads to the differentiation of stem line T-cells to helper T cells (Diehl and Rincon, 2002) 
whereas in the gastro-intestinal tract, IL-6 and its receptors on epithelial cells contribute 
to peripheral disorders such as colitis and Crohn’s disease (Mudter and Neurath, 2007). 
However, studies examining IL-6 receptor signaling or trans-signaling in the CNS are 
limited and we are aware of no studies examining the extent to which IL-6 receptor 
signaling affects neuroinflammation and infection-related changes in behavior.   
Therefore the purpose of this study was to assess classical and trans-signaling in 
neurons and microglia and determine if inhibiting IL-6 receptor signaling in the brain is 
sufficient to inhibit sickness behavior caused by peripheral infection. The important 
results showed treatment with sgp130 attenuated LPS-induced receptor activation and 
production of IL-6 and enhanced recovery of sickness behavior. These findings suggest 
that inhibition of excessive production of IL-6 through its signaling pathways during 
infection may be helpful in preventing behavioral deficits. 
4.3 Materials and methods 
BV.2 microglial and Neuro.2A neuronal cell culture 
The murine microglia cell line, BV.2 (a gift from Linda Van Eldik, Northwestern 
University, Evanston, IL) and neuronal Neuro.2A cells (purchased from ATCC) have 
been used as a model to investigate the neuroimmune system (Jang et al., 2008; Zorina 
et al., 2010). Cells were maintained in 150-cm2 tissue culture flasks (BD Falcon, 
Franklin Lakes, NJ) in DMEM (Bio-Whittaker, Cambrex, MD) supplemented with 10% 
FBS (Hyclone, Logan, UT),  200 mM glutamine, and 100 units/ml penicillin/streptomycin 
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(Invitrogen, Carlsbad, CA) at 37°C in a humidified incubator under 5% CO2. Confluent 
cultures were passed by trypsinization. Cells were centrifuged (5 minutes (min) at 27°C, 
200 × g), and culture medium was removed. In all experiments, cells were re-
suspended in DMEM supplemented with 10% FBS and seeded in six-well plates (BD 
Falcon, Franklin Lakes,NJ) at a population of 3 ×105 - 5 × 105 cells per well overnight at 
37°C in a humidified incubator under 5% CO2 before treatments. Cells were treated with 
sterile saline containing 0.1% BSA (vehicle), sIL-6R, or sgp130 (R&D systems, 
Minneapolis, MN) for 1 hour (h) followed by treatment with recombinant IL-6 (R&D 
systems, Minneapolis, MN) or Escherichia coli LPS (serotype 0127:B8 Sigma, St. Louis, 
MO), for 20 min or 3 h, respectively. 
Flow cytometry 
Flow cytometric analysis of microglial and neuronal cell surface markers was 
performed as described previously, with a few modifications (Henry et al., 2008). In 
brief, Fc receptors on BV.2 microglia cells were blocked with anti-CD16/CD32 antibody 
(eBioscience, San Diego, CA) in a PBS-1% BSA/sodium azide solution, and incubated 
with anti-CD126-Phycoerythrin (PE) and anti-CD130-Allophycocyanin (APC) or anti-
TLR-4 PE (eBiosciences, San Diego, CA), fluorescently labeled isotype antibodies for 
PE and APC (eBiosciences, San Diego, CA) were used for controls. Expression of 
surface receptors was determined using a Becton-Dickinson LSR II Flow Cytometer 
(Red Oaks, CA). Fifty thousand events were collected and flow data were analyzed 
using FCS Express software (De Novo Software, Los Angeles, CA).  
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Animals and surgery 
Adult (3-6 months) male BALB/c mice obtained from our in-house breeding 
colony were used in all experiments. Mice were housed in polypropylene cages and 
maintained at 21°C under a reverse-phase 12 h light-dark cycle (lights off at 07:00) with 
ad libitum access to water and rodent chow.  
Surgery: Intracerebroventricular (icv) cannulation was performed under aseptic 
conditions as described previously (Abraham et al., 2008). In brief, mice were deeply 
anesthetized with an intraperitoneal (i.p.) injection of ketamine and xylazine (100 and 10 
mg/kg, respectively) and the surgical site was shaved and sterilized. They were 
positioned in a stereotaxic instrument (David Kopf Instruments, Tujunga, CA) so that the 
frontal and parietal bones of the skull were parallel to the surgical platform. An incision 
roughly 1.5 cm in length was made on the cranium to reveal the bregma and a 26-
gauge stainless steel cannula (Plastics One, Roanoke, VA) was placed in the right 
lateral cerebral ventricle according to predetermined stereotaxic coordinates (lateral 1.6 
mm and antero-posterior 1mm to the bregma, and horizontal 2 mm from the dura 
mater). The cannula was secured using two adjacent stainless steel screws and 
cranioplastic cement (Plastics One, Roanoke, VA). A dummy cannula (Plastics One, 
Roanoke, VA) was inserted in the guide cannula to prevent occlusion and infection. 
Mice were injected subcutaneously with buprenorphine (0.05 mg/kg) following surgery 
and then again 8-12 h later to aid with any post-operative discomfort. Mice were 
provided a minimum of seven days to recover from any discomfort or weight loss before 
any treatment or behavioral test. Accurate placement of the cannula was confirmed by 
allowing 2µl of sterile saline to flow via gravity into the lateral ventricle. If cannula 
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placement could not be confirmed, the animal was excluded from the study. All 
procedures were in accordance with the National Institutes of Health Guidelines for the 
Care and Use of Laboratory Animals and were approved by the University of Illinois 
Institutional Animal Care and Use Committee. 
Animal studies 
Mice were handled 1-2 min each day for seven days before experimentation to 
acclimate them to routine handling. On test day, animals were injected icv with sterile 
saline containing 0.1% BSA (vehicle) or 100 ng sgp130 dissolved in 2µl vehicle. At the 
same time as the icv injection, mice were injected i.p. with sterile saline or LPS (0.33 
mg/kg BW or 10µg, serotype 0127:B8, Sigma, St. Louis, Mo.). The LPS dosage was 
selected because it elicits a proinflammatory cytokine response in the brain, which 
results in mild transient sickness behavior in adult mice (Berg et al., 2004). Tests were 
conducted during the dark phase (between 07:00 and 19:00) of the light/dark cycle 
under infrared lighting to aid video recording. Baseline behavior was taken just before 
treatment administration (0 h) and 4, 8, and 24 h afterwards.   
To measure changes in cytokines and signaling molecules, mice not exposed to 
the behavior paradigms were injected icv with vehicle or sgp130 (100 ng) and i.p. with 
sterile saline or LPS (10 µg) and killed 8 h later by CO2 asphyxiation. Blood samples 
were collected via cardiac puncture into EDTA-coated syringes to obtain plasma, and 
the brain was rapidly removed and dissected to obtain hippocampal tissue. Plasma and 
hippocampal tissue were snap-frozen in liquid nitrogen and stored at -80oC until later 
analysis.   
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Behavioral tests 
 Social exploratory behavior: To assess motivation to engage in social 
exploration, a novel male juvenile conspecific (20-30 days old) from our in-house colony 
was introduced into the test subject's home cage for a 7 min period. Mice were video 
recorded, and the duration engaged in social investigation was determined from the 
video records by a trained observer who was blind to experimental treatments. Social 
behavior was determined as the amount of time that the experimental animal spent 
investigating (e.g. trailing, anogenital sniffing) the juvenile. Baseline social behavior was 
determined for all experimental treatments at the 0 h, for a 7 min period. Statistical 
analysis revealed there were no significant differences between treatment groups at 
baseline. The results are expressed as percent depression in time engaged in social 
behavior compared to respective baseline measures.  
Western immunoblotting  
To assess IL-6 receptor signaling in CNS cells in vitro, BV.2 and Neuro.2A cells 
were harvested and in vivo, mouse hippocampal tissue were allowed to thaw, and lysed 
in ice cold lysis buffer containing: 100 mM HEPES (7.5 pH), 150 mM NaCl, 1% Nonidet 
P-40 (U.S. Biological, Swampscott, MA), 2 mM EGTA, 2 mM Sodium Orthovanadate, 
Protease Inhibitor cocktail (100 mM EDTA, 1 µg/mL AEBSF, Bestatin, Pepstatin A, 
Leupeptin, Aprotinin, and E-64), and 1mM PMSF and centrifuged at 11000 × g for 10 
min at 4oC to remove all cellular debris. Protein concentration was determined using the 
BCA Protein Assay according to the manufacturer’s protocol (Bio-Rad, Hercules, CA). 
Lysate concentration was then normalized and denatured in SDS/PAGE buffer at 95oC 
and stored at -20oC until use. All lysates were electrophoresed and separated on a 
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7.5% SDS-PAGE gel, and transferred onto nitrocellulose membranes (GE Healthcare, 
Minneapolis, MN). The membranes were blocked with 5% non-fat milk and incubated 
with anti-phosphorylated STAT3 (tyr-705) antibody (Cell Signaling, Danvers, MA) 
overnight at 4°C. After incubation with an HRP-conjugated secondary antibody, the 
protein bands were detected with a chemiluminescenct substrate (Cell Signaling, 
Danvers, MA) and Bio-Max film (Eastman Kodak Company, Rochester, NY). For 
detection of total STAT3 protein, the membranes were stripped with stripping buffer (2% 
SDS, 6.25 mM Tris.HCL (6.8 pH), 0.70% β-ME) followed by overnight incubation with 
anti-STAT3 antibody (Cell Signaling, Danvers, MA) at 4°C.  Immunoblot results were 
quantified using ImageJ 1.41 software (NIH). 
Cytokine detection in cell supernatant, hippocampus, and plasma 
 Hippocampal tissue was lysed in ice cold lysis buffer and protein concentrations 
were determined using the BCA protein assay according to manufacturer’s protocol. For 
hippocampal tissue, the antibodies and standards for the IL-6 ELISA were used 
according to the description by the manufacturer (eBiosciences San Diego, CA). Cell 
supernatants and plasma samples were assayed for IL-1β, TNF-α, IL-6, and the anti-
inflammatory cytokine IL-10, using multiplexed bead-based immunoassay kits combined 
with a Cytokine Reagent kit as described by the manufacturer (Bio-Rad, Hercules, CA).  
Cytokine mRNA measurement by quantitative real-time PCR 
Total RNA from hippocampus was isolated using the Tri Reagent protocol 
(Sigma, St. Louis, MO.) A QuantiTect Reverse Transcription Kit (Qiagen, Valencia, CA) 
was used for cDNA synthesis with integrated removal of genomic DNA contamination 
according to the manufacturer’s protocol. Quantitative real time PCR was performed 
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using the Applied Biosystems (Foster, CA) Assay-on Demand Gene Expression 
protocol as previously described (Krzyszton et al., 2008). In brief, cDNA was amplified 
by PCR where a target cDNA (IL-6, Mm00446190_m1; IL-1β, Mm00434228_m1; TNF-
α, Mm00443258_m1; IL-10, Mm00439616_m1, IL-6R, 00439653_m1; and gp130, 
mM00439665_m1) and a reference cDNA (glucose-3 phosphate dehydrogenase, 
Mm99999915_g1) were amplified simultaneously using an oligonucleotide probe with a 
5’ fluorescent reporter dye (6-FAM) and a 3’ quencher dye (NFQ). PCR reactions were 
performed in triplicate under the following conditions: 50oC for 2 min, 95oC for 10 min, 
followed by 40 cycles of 95oC for 15 sec and 60oC for 1 min. Fluorescence was 
determined on an ABI PRISM 7900HT-sequence detection system (Perkin Elmer, 
Forest City, CA). Data were analyzed using the comparative threshold cycle (Ct) 
method, and results are expressed as fold difference. 
Statistical analysis 
All data were analyzed using the ANOVA routine in Statview and MIXED 
procedure of the Statistical Analysis System software (SAS Inst., Cary, NC). Data were 
subjected to a univariate analysis to ensure normality. Behavioral data were subjected 
to a three-way ANOVA (sgp130 × LPS × time) using repeated measures in which Time 
(0, 4, 8, and 24 h) was a within subjects measure, and sgp130 and LPS were between 
subjects measures. Cytokine mRNA and protein levels were analyzed using a two-way 
ANOVA (sgp130 × LPS).  Phosphorylation of STAT3 levels were analyzed using a two-
way ANOVA (sIL-6R or sgp130× LPS). Post hoc Student’s t test of least square means 
was used to determine if treatment means were significantly different from one another 
(p<0.05). All data are presented as mean ± standard error of the mean (SEM). 
87 
 
4.4 Results 
IL-6 and LPS induce STAT3 phosphorylation in microglia and neurons 
To verify the presence of the subunits involved in IL-6 and LPS signaling, the cell 
surface expression of IL-6R, gp130, and TLR-4 on BV.2 and Neuro.2A cells was 
examined. Figure 4.1A shows more than 50% of the microglial BV.2 cells expressed 
gp130 while nearly 90% expressed IL-6R; approximately 50% of the BV.2 cells 
expressed both IL-6R and gp130. In contrast, about 90% of the Neuro.2A cells 
expressed gp130, 3% expressed IL-6R, and 3% co-expressed IL-6R and gp130. 
Approximately 80% of the BV.2 cells expressed TLR-4 compared to 30% of the 
Neuro.2A cells (Figure 4.1B). Although IL-6 can activate multiple transcription factors 
(e.g., STAT3, AP-1, CREB), in CNS cells activation of the IL-6 receptor upregulates 
STAT3 phosphorylation (Heinrich et al., 1998; Marz et al., 1999; Schobitz et al., 1995). 
Thus, the capacity of IL-6 to induce the phosphorylation of STAT3 in BV.2 and 
Neuro.2A cell cultures was examined. Figure 4.2 shows that IL-6 at a higher 
concentration (50 ng/mL) increased phosphorylated STAT3 similarly in microglia and 
neurons. However, at a lower concentration (10 ng/mL), IL-6 only increased STAT3 
phosphorylation in microglia, which is consistent with the greater proportion of these 
cells that expressed IL-6R. These findings suggest that classic and trans-signaling can 
occur on both neurons and microglia, although neurons may be more readily regulated 
through the mechanism of trans-signaling since gp130 is highly expressed on this cell 
type. 
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IL-6 trans-signaling in microglia and neurons  
Previous studies have shown that gp130 is expressed constitutively on all cell 
types (Dreuw et al., 2004; Taga and Kishimoto, 1997) and this expression facilitates 
trans-signaling in the presence of IL-6 and sIL-6R (Jones et al., 2005; Jones and Rose-
John, 2002; Rosejohn and Heinrich, 1994). Figure 4.3A shows that pretreatment of 
microglia and neurons with sIL-6R significantly increased IL-6-induced STAT3 
phosphorylation. Consistent with the increase in STAT3 phosphorylation, a sIL-6R × 
LPS interaction was evident whereby sIL-6R upregulated LPS-induced IL-6 production 
in microglia (p<0.05), and neurons (p<0.04, Figure 4.4). Although not statistically 
significant, there was some constitutive STAT3 phosphorylation and IL-6 expression in 
samples pretreated with sIL-6R (Figures 4.3 and 4.4). 
sgp130 attenuated IL-6R activation in microglia and neurons 
We next investigated the ability of sgp130 to alter phosphorylation of STAT3 and 
expression of IL-6. A sgp130 × LPS interaction revealed that pretreatment of BV.2 
microglial (p<0.03) and Neuro.2A neuronal (p<0.02) cells with sgp130 decreased LPS-
induced activation of STAT3 and inhibited LPS-induced IL-6 production in both BV.2 
and Neuro.2A cells (Figures 4.5 and 4.6, respectively). These data demonstrate that 
sgp130 inhibits LPS-induced IL-6 production in microglia and neurons. The LPS-
induced secretion of IL-1β, TNF-α, and IL-10 was not affected by sgp130 (data not 
shown). 
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sgp130 inhibits LPS-induced sickness behavior 
Brain microglia and neurons produce inflammatory cytokines, including IL-6, that 
induce sickness behavior. Given the in vitro results, we investigated the effect of 
centrally administered sgp130 on LPS-induced sickness behavior. Social exploratory 
behavior was used to measure sickness. Three-way ANOVA of social behavior revealed 
a significant LPS × time × sgp130 interaction (p<0.01). As expected, LPS treatment 
decreased social exploratory behavior in a time-dependent manner.  LPS induced 
transient sickness, as the behavior of mice given LPS returned to baseline by 24 h post-
injection (Figure 4.7). However, behavior of mice treated icv with sgp130 prior to LPS 
returned to normal sooner. That sgp130 did not inhibit LPS-induced sickness behavior 
at 2 or 4 h after LPS treatment but did later, suggests the IL-6 trans-signaling pathway is 
important for maintaining sickness behavior but not for its induction.  
sgp130 attenuated STAT3 phosphorylation and IL-6 gene expression and protein 
in the brain 
Because sgp130 inhibited LPS-induced sickness behavior 8 h post-injection, 
hippocampal tissue and plasma was collected from a separate group of sgp130- and 
LPS-treated mice at the 8 h time point to assess STAT3 phosphorylation and IL-6 
expression. Similar to the in vitro results, i.p. LPS upregulated STAT3 phospho-protein 
in the hippocampus. There was a sgp130 × LPS interaction (p<0.001) whereby STAT3 
phosphorylation was blunted when mice were given icv sgp130 (Figure 4.8B). There 
was also a significant sgp130 × LPS interaction (p<0.02) whereby sgp130 decreased 
the amount of LPS-induced IL-6 mRNA in the hippocampus, although it did not 
significantly affect IL-1β or TNF-α mRNA (Figure 4.6B). To determine if the effect of 
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sgp130 was also apparent at the protein level, LPS-induced IL-6 protein was measured. 
As expected, LPS alone increased IL-6 protein in the hippocampus; however, a sgp130 
× LPS interaction (p<0.0001) indicated that co-administration of sgp130 inhibited the 
LPS-induced increase in IL-6 (Figure 4.9B). Taken together, these results show that 
sgp130-related changes in LPS-induced social behavior are paralleled by sgp130-
associated changes in the brain. 
To assess the effect of icv sgp130 on the peripheral cytokine response to i.p. 
LPS, plasma was assayed for IL-1β, IL-6, IL-10, and TNF-α. Plasma levels of all four 
cytokines was increased after LPS treatment and this was not affected by sgp130 
(Table 1), suggesting icv sgp130 acts locally in the brain.  
4.5 Discussion  
Bi-directional communication between the periphery and the brain is important for 
the appropriate response to an immune stimulus (Dantzer et al., 1998). During 
peripheral infection, pro-inflammatory cytokines are produced in the brain and play a 
role in adaptive sickness behavior. However, an excessive cytokine response in the 
brain is associated with prolonged sickness behavior (Abraham and Johnson, 2009a; 
Combrinck et al., 2002; Godbout et al., 2005b; Huang et al., 2008), cognitive deficits 
(Campbell et al., 1993; Chen et al., 2008; Heyser et al., 1997), and increased anxiety 
(Mines et al., 2010; Sparkman and Johnson, 2008); and the specific role of IL-6 has not 
been extensively studied. We investigated the capacity of sgp130 to block IL-6 
production in microglia and neurons in vitro and explored the effects of sgp130 on LPS-
induced sickness behavior in vivo. In vitro, sgp130 attenuated LPS-stimulated IL-6R 
activation along with IL-6 protein release in both microglial (BV.2) and neuronal 
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(Neuro.2A) cell types. Moreover, in vivo experiments showed that icv sgp130 facilitated 
recovery from LPS-induced sickness, and this sgp130-associated recovery was 
paralleled by reduced IL-6 mRNA and protein levels in the hippocampus. 
The present study demonstrates that murine microglia and neurons have the 
potential to produce IL-6 through both a classic and trans-signaling pathway. In two-
color flow cytometry experiments, we showed that BV.2 and Neuro.2A cells expressed 
both gp130 and IL-6R on their cell surface, though expression differed in each cell type. 
The findings indicate that classic and trans-signaling are important on both neurons and 
microglia, though neurons may be more readily regulated through the mechanism of 
trans-signaling. Previous studies report that the presence of the sIL-6R elicits an 
exaggerated production of IL-6 protein (Jones and Rose-John, 2002; Mizuguchi et al., 
2001; Nancey et al., 2008). Consistent with these reports, we found that pretreatment of 
sIL-6R led to an IL-6- and LPS-induced increase of IL-6 protein in microglia and 
neurons. This response is presumably elicited by the ligand and soluble receptor 
forming a sIL-6R/IL-6 complex. This complex has the ability to bind to the gp130 trans-
membrane receptor signal transducer and activate intracellular signals that produce IL-6 
in any cell type via this trans-signaling mechanism.  
LPS binds TLR-4, which we confirmed was present on both microglia and 
neurons (Figure 4.1C and D). Upon binding, LPS induces upregulation of the NF-κB 
transcription factor that binds promoter regions to stimulate the production of IL-6 along 
with a milieu of other cytokines (e.g. IL-1β, TNF-α, and IL-10) (Laflamme and Rivest, 
2001). Soluble gp130 inhibits IL-6 trans-signaling but also regulates IL-6 related 
cytokines oncostatin M (OSM) and leukemia inhibitory factor (LIF). However, sgp130 
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has a much lower affinity for OSM and LIF than for the IL-6/sIL-6R complex (Jostock et 
al., 2001) and would not be expected to affect either cytokine at the dose used here 
(Jostock et al., 2001; Modrell et al., 1994). Therefore, using sgp130 allowed us to 
investigate the effects of IL-6 after LPS treatment, while leaving all other cytokines 
unaffected. 
Successful activation of the IL-6R is noted by the dimerization of gp130, resulting 
in an intracellular cascade that forms recruitment sites for STAT3 in the cytoplasmic 
region. STAT3 homodimerizes, autophosphorylates, then translocates to the nucleus 
and binds to enhancer elements of IL-6 to induce gene transcription. Here, STAT3 was 
upregulated in response to both IL-6 and LPS in BV.2 and Neuro.2A cells and 
pretreatment with sIL-6R led to an increased IL-6- and LPS-induced STAT3 
phosphorylation.  However, when pretreated with sgp130, IL-6 and LPS-stimulated BV.2 
and Neuro.2A cells displayed a decrease in STAT3 phosphorylation. These data agree 
with other studies using sgp130 to inhibit IL-6 signaling in peripheral models of 
inflammation such as arthritis, peritonitis, and colitis (Coles et al., 2007; McLoughlin et 
al., 2005; Richards et al., 2006). To our knowledge, this is the first study to report that 
pretreatment with sgp130 attenuated LPS-induced IL-6 protein secretion in CNS-
derived cells. 
LPS activation of the peripheral innate immune system stimulates a robust 
secretion of inflammatory cytokines through the NF-κB pathway and these cytokines are 
relayed to the CNS via vagal nerve afferents, and humoral and diffusive pathways 
(Maier et al., 1998; Quan, 2008). Once in the brain this inflammatory signal is mimicked 
by innate immune cells (Block et al., 2007; Kreutzberg, 1996; Ransohoff and Perry, 
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2009) and targets neurons which elicit a sickness behavior response that includes 
general malaise, decreased activity, decreased social interaction, decreased food and 
water intake (weight loss), and sleep dysregulation (Dantzer et al., 1998; Kelley et al., 
2003; Maier and Watkins, 1998). We therefore investigated the effects of icv sgp130 in 
vivo and hypothesized that, given the role of IL-6 in neuroinflammatory responses; it 
would attenuate LPS-induced sickness behavior and IL-6 production. Here we show 
that sgp130 was effective in facilitating the recovery from LPS-induced social 
exploratory behavior as early as 8 h in mice. In addition to facilitating recovery from 
LPS, sgp130 attenuated receptor activation, gene expression, and production of IL-6 in 
adult mice 8 h after LPS injection. Consistent with previous studies (Berg et al., 2004; 
Godbout et al., 2004; Godbout et al., 2005a; Henry et al., 2008), a reduction in brain 
cytokines did not prevent the initial induction of LPS-induced sickness behavior seen at 
2-4 h post-injection, but rather facilitated the recovery from sickness starting at the 8 h 
time point (Jones and Rose-John, 2002; Mizuguchi et al., 2001; Nancey et al., 2008). In 
this model, the inability of sgp130 to block the onset of sickness behavior can be 
attributed to the fact that LPS induces multiple proinflammatory cytokines that have 
redundant properties and inhibition of a single cytokine is not sufficient to block the 
initial sickness. Notably, a study showed that LPS-induced sickness behavior was 
blocked only if IL-1β, IL-6, and TNF-α were antagonized simultaneously (Swiergiel and 
Dunn, 1999). 
This facilitation in recovery from LPS-induced sickness has been observed in 
various nutritional and pharmacological interventions (Abraham and Johnson, 2009a, b; 
Berg et al., 2005; Richwine et al., 2005) and may be of particular importance when 
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considering conditions where an exaggerated response is elicited during a primed 
inflammatory state, such as in overexpressing transgenic animals (Campbell et al., 
1993; Heyser et al., 1997), prion disease (Combrinck et al., 2002), and aging (Chen et 
al., 2008; Godbout et al., 2005b; Huang et al., 2008).  We have previously 
demonstrated that aged animals display an exaggerated neuroinflammatory and 
sickness behavior response after activation of the peripheral immune system (Godbout 
et al., 2005b) and it appears that primed microglia are responsible for this exacerbated 
phenotype (Godbout et al., 2004; Sparkman and Johnson, 2008; Ye and Johnson, 
1999). We and others have shown interventions that are anti-inflammatory are able to 
ameliorate the exaggerated cytokine response in the brain as well as the mal-adaptive 
behavioral response that results from peripheral infection (Abraham and Johnson, 
2009a, b; Berg et al., 2005; Henry et al., 2008; Jang et al., 2010; Richwine et al., 2005). 
Based on the data obtained from this study, it is possible that sgp130 will abrogate the 
prolonged LPS-induced alterations in sickness behavior, cognition, as well as 
exaggerated IL-6 levels exhibited in aged mice. 
Studies have highlighted the potential therapeutic role of sgp130 in treating 
inflammation; it has been shown to suppress the severity of experimentally-induced 
arthritis, modulate leukocyte trafficking, and mitigate the effects of colitis and colon 
cancer (Atreya et al., 2000; Chen et al., 2004; Fielding et al., 2008; Jones et al., 2005; 
Richards et al., 2006). The current study is the first to extend the body of literature and 
show the effectiveness of sgp130 in inhibiting IL-6 signaling in cells of the CNS and in 
brains of animals.  The present results suggest that the use of sgp130 as an inhibitor of 
the IL-6 pathway in an array of inflammatory conditions, from arthritis to 
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neuroinflammatory disorders, may mitigate IL-6 expression and have a beneficial effect 
on behavioral responses. 
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4.6 Figures  
 
       
 
Figure 4.1: Differential expression of IL-6R, gp130, and TLR-4 on microglia and neurons. 
A and B) Two-color dot plot; cells were incubated with anti-CD126-PE and anti-CD130-APC and 
expression of the cell surface markers were assessed on microglia and neurons. C and D) 
Single-parameter histograms; cells were incubated with anti-TLR-4-PE and compared with  
isotype controls.  
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Figure 4.2:  IL-6-induced STAT3 expression in BV.2 microglial and Neuro.2A neuronal 
cells.  IL-6 receptor activation in BV.2 and Neuro.2A cells was verified by STAT3 
phosphorylation 20 min after treatment with 10 and 50 ng/mL of IL-6. Bars represent the mean ± 
SEM. Results are an average of 5 independent experiments. Means with different letters are 
significantly different from one another (p<0.05). 
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Figure 4.3:  IL-6 trans-signaling in BV.2 microglia and Neuro.2A cells.  
BV.2 and Neuro2A cells were pre-treated for 1 h with 25 ng/mL sIL-6R and A) IL-6-induced 
STAT3 phosphorylation. B) Bars represent the mean ± SEM. Results are an average of 5 
independent experiments. Means with different letters are significantly different from one 
another (p<0.05). 
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Figure 4.4:  IL-6 trans-signaling in BV.2 microglia and Neuro.2A cells. LPS-induced IL-6 
protein secretion was measured at 3 h. Bars represent the mean ± SEM. Results are an 
average of 5 independent experiments. Means with different letters are significantly different 
from one another (p<0.05). 
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Figure 4.5: sgp130 attenuation of LPS-induced STAT3 phosphorylation in Neuro.2A and 
BV.2 cells. BV.2 microglia and Neuro.2A neuronal cells were pre-treated for 1 h with 100 ng 
sgp130 and A) LPS-induced STAT3 phosphorylation was measured. B) Bars represent the 
mean ± SEM. Results are an average of 5 independent experiments. Means with different 
letters are significantly different from each other (p<0.05). 
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Figure 4.6: sgp130 attenuation of LPS-induced STAT3 phosphorylation in Neuro.2A and 
BV.2 cells.  IL-6 protein secretion was measured. Bars represent the mean ± SEM. Results are 
an average of 5 independent experiments. Means with different letters are significantly different 
from each other (p<0.05). 
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Figure 4.7: sgp130 facilitates recovery from LPS-induced sickness behavior. Mice were 
injected icv with vehicle or 100 ng sgp130 and i.p. with sterile saline or LPS.  Social exploratory 
baseline behavior was measured before LPS injection and at 2, 4, 6, 8, and 24 h post-injection. 
Bars represent the mean ± SEM (n = 11-12) Means with * are statistically different (p<0.05) from 
saline controls. 
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Figure 4.8: sgp130 reduces IL-6 receptor activation, gene expression, and protein 
secretion in vivo.  Hippocampal tissue was collected 8 h after icv sgp130 and i.p. LPS and 
assayed for STAT3 phosphorylation. Bars represent the mean ± SEM (n = 8-9) Means with 
different letters are statistically different from each other (p<0.05). 
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Figure 4.9: sgp130 reduces IL-6 gene expression, and protein secretion in vivo.  
Hippocampal tissue was collected 8 h after icv sgp130 and i.p. LPS and assayed for A) mRNA 
levels of IL-6¸IL-1β, and TNF-α, B) and IL-6 protein. sgp130 reduced LPS- mRNA levels of IL-6, 
but not IL-1β or TNF-α, and IL-6 protein in the hippocampus. Bars represent the mean ± SEM (n 
= 8-9) Means with different letters are statistically different from each other (p<0.05). 
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4.7 Table 
Table 1. Plasma cytokines 8 h after sgp130 and LPS. 
 Vehicle (icv) sgp130 (100 ng) (icv)  p-values                     
 
Saline (i.p.) 
LPS (10 µg) 
(i.p.) 
Saline (i.p.) 
LPS (10µg) 
(i.p.) 
sgp130 LPS 
sgp130 
× LPS 
IL-1β 
206.82 ± 
86.19 
1113.12 ± 
24.48 
191.10 ± 
85.12 
1543 ± 695.96 0.537 0.009* 0.513 
IL-6 
142.87 ± 
117.79 
2873.03 ± 
994.50 
96.50 ± 
8.41 
2682.06 ± 
669.86 
0.820 0.001* 0.955 
TNF-α 
325.89 ± 
54.60 
987.55 ± 
104.77 
322.95 ± 
73.31 
947.93 ± 
119.32 
0.829 <0.0001* 0.852 
IL-10 
56.39 ± 
23.01 
407.34 ± 
92.56 
46.72 ± 
11.47 
447.22 ± 
174.13 
0.764 0.002* 0.719 
Bio-Plex ProTM  assay: units = pg/mL 
*a significant difference per treatment group (p<0.05) 
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Chapter 5 
Interleukin-6 trans-signaling in the senescent mouse brain is involved in 
infection-related deficits in contextual fear conditioning 
 
5.1 Abstract 
Excessive production of pro-inflammatory cytokines in the senescent brain in 
response to peripheral immune stimulation is thought to induce behavioral pathology, 
however, few studies have examined if the increase in pro-inflammatory cytokines is 
accompanied by an increase in cytokine signaling. Here, we focused on IL-6 as a 
prototypic pro-inflammatory cytokine and used phosphorylated STAT3 as a marker of 
IL-6 signaling. In an initial study, IL-6 mRNA and the magnitude and duration of STAT3 
activation were increased in the hippocampus of senescent mice compared to adults 
after i.p. injection of lipopolysaccharide (LPS). The LPS-induced increase in STAT3 
activity was ablated in aged IL-6-/- mice, suggesting IL-6 is a key driver of STAT3 activity 
in the aged brain. To determine if IL-6 activated the classical or trans-signaling pathway, 
before receiving LPS i.p., aged mice were injected icv with sgp130, an antagonist of the 
trans-signaling pathway. Importantly, the LPS-induced increases in both IL-6 and 
STAT3 activity in the hippocampus were inhibited by sgp130. To assess hippocampal 
function, aged mice were injected icv with sgp130 and i.p. with LPS immediately after 
the acquisition phase of contextual fear conditioning, and immobility was assessed in 
the retention phase 48 hours (h) later. LPS reduced immobility in aged mice, indicating 
immune activation interfered with memory consolidation. However, sgp130 blocked the 
deficits in contextual fear conditioning caused by LPS. Taken together, the results 
suggest IL-6 trans-signaling is increased in the senescent brain following peripheral 
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LPS challenge and that sgp130 may protect against infection-related neuroinflammation 
and cognitive dysfunction in the aged.   
5.2 Introduction 
 Interleukin-6 (IL-6) has a role in cognitive dysfunction.  For example, 
immunoneutralization of IL-6 lengthened long-term potentiation (LTP) and improved 
spatial alternation behavior (Balschun et al., 2004) while IL-6-deficient mice were 
refractory to lipopolysaccharide (LPS)-induced deficits in working memory (Sparkman et 
al., 2006). IL-6 also disrupts neurogenesis (Vallieres et al., 2002) and is up regulated in 
an array of neurodegenerative diseases (Gruol and Nelson, 1997; Hofmann et al., 2009; 
Licastro et al., 2003; Muller et al., 1998). Furthermore, in senescence, constitutive 
expression of IL-6 by brain microglia is up regulated (Godbout and Johnson, 2004; Ye 
and Johnson, 1999, 2001) and during infection there is excessive production of pro-
inflammatory cytokines including IL-6, leading to prolonged sickness behavior (Abraham 
and Johnson, 2009; Godbout et al., 2005; Huang et al., 2008), cognitive deficits 
(Barrientos et al., 2006; Chen et al., 2008; Rosczyk et al., 2008), affective disorders 
such as increased anxiety and depression (Godbout et al., 2008; Kiecolt-Glaser et al., 
2003), and even atrophy of neurons (Richwine et al., 2008).  These findings in rodents 
have led us to speculate that the acute cognitive disorders seen in older adults with an 
infection are due to excessive production of pro-inflammatory cytokines in the brain, 
although very little is known regarding the effects of aging on cytokine receptor 
signaling. 
The IL-6 receptor is activated through two separate, but related pathways termed 
classical and trans-signaling. The receptor consists of two subunits: the IL-6 receptor-
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alpha chain (IL-6R), which binds IL-6, and the transmembrane signaling subunit, 
glycoprotein 130 (gp130), which is the intracellular signal transducer and is expressed 
across all cell types. Classical activation consists of the IL-6 ligand binding to the 
membrane-bound IL-6R. It is important to note that both receptor subunits (IL-6R and 
gp130) can be cleaved immediately before the membrane spanning region by 
alternative splicing or shed by proteolytic enzymes to produce a soluble receptor 
located in extracellular matrix.  The expression of membrane-bound IL-6R is generally 
limited to a few cells of the immune system, while gp130 is ubiquitously expressed 
(Heinrich et al., 1998; Kishimoto et al., 1992). Thus, the basis of trans-signaling is the 
ability of soluble IL-6R (sIL-6R) to bind IL-6 in the extracellular compartment to form an 
IL-6/sIL-6R complex; this complex has an increased binding affinity to membrane-bound 
gp130 when compared to IL-6 alone. This mechanism of action confers IL-6 
responsiveness in any cell type that expresses gp130 (Jones et al., 2005; Rose-John 
and Heinrich, 1994). 
Upon binding through either the classical or trans-signaling pathway, gp130 
dimerizes and autophosphorylates, resulting in the activation of Janus kinase-1 and 2 
(Jak1 and Jak2). These tyrosine kinases phosphorylate the cytoplasmic region of gp130 
creating recruitment sites for signal transducer and activation of transcription-3 
(STAT3), a Src-homology-2 (SH2) domain-containing signaling molecule. Activated 
STAT3 forms a dimer, autophosphorylates, and translocates to the nucleus where it 
binds to enhancer elements of the IL-6 promoter region. Thus the main consequence of 
both classical or trans-signal IL-6 receptor action is to induce gene transcription and 
subsequent synthesis and secretion of IL-6, although trans-signaling allows this in many 
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more cell types (Heinrich et al., 1998). sIL-6R and soluble gp130 (sgp130) have varying 
effects on circulating IL-6. sgp130 acts as a partial antagonist, or decoy receptor, by 
binding the IL-6/sIL-6R complex and preventing it from binding membrane-bound gp130 
to initiate signal transduction (Jostock et al., 2001).  
Neurons do not seem to express appreciable amounts of IL-6R, however, they 
do express large amounts of gp130 (Burton et al., 2011; Schobitz et al., 1993), alluding 
to the importance of IL-6 trans-signaling in the brain. Indeed IL-6 trans-signaling in the 
brain was recently shown to play a pivotal role in mediating LPS-induced sickness 
behavior (Burton et al., 2011). Other studies have begun to reveal the anti- versus pro-
inflammatory actions of IL-6, as trans-signaling appears to elicit a pro-inflammatory 
response by causing non-immune cells to produce IL-6 which in turn recruits immune 
cells to the local site (Barkhausen et al., 2011; Barrientos, 2011; Greenhill et al., 2011; 
Scheller et al., 2011).  
Although IL-6 is increased in the brain of senescent mice, to our knowledge there 
have been no studies examining the extent to which peripheral infection influences IL-6 
trans-signaling in the brain or its role in cognitive dysfunction.  Thus, the present study 
investigated hippocampal STAT3 activation as a marker for IL-6 signaling and 
hippocampal-dependent learning and memory in aged mice after peripheral injection of 
LPS.  We further investigated the extent to which inhibition of IL-6 trans-signaling with 
sgp130 would mitigate STAT3 activation and deficits in learning and memory.  The 
important results suggest that IL-6 trans-signaling is increased in the hippocampus of 
aged mice after LPS and that IL-6 trans-signaling plays a key role in LPS-induced 
deficits in hippocampal-dependent learning and memory.      
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5.3 Materials and Methods 
Animals and surgery 
 Adult (3-6 months) and aged (22-24 months) male BALB/c, C57BL/6 (IL-6+/+ ) 
and IL-6 knockout B6.129S2-Il6tm1 Kopf/J (IL-6-/-) (Kopf et al., 1994) mice were used. 
All BALB/c mice were obtained from our in-house colony whereas the IL-6+/+ and IL-6-/- 
mice were purchased from Jackson Laboratory (Bar Harbor, ME).  The IL-6+/+ and IL-6-/- 
mice were 2-months old upon receipt.  Mice were housed in polypropylene cages and 
maintained at 21°C under a reverse-phase 12-h light-dark cycle with ad libitum access 
to water and rodent chow. At the end of each study, mice were examined post mortem 
for gross signs of disease (e.g., tumors or splenomegaly). Data from mice determined to 
be unhealthy were excluded from the analysis (< 5%). 
Surgery: For some experiments intracerebroventricular (icv) cannulation was 
performed as described previously (Abraham et al., 2008). Immediately after surgery 
and again 8-12 hours (h) later mice received buprenorphine (0.05 mg/kg s.c.) to aid with 
any post-operative discomfort. Mice were provided a minimum of 7 days to recover 
before initiating an experiment.  Accurate placement of the cannula was confirmed by 
allowing 2 µl of sterile saline to flow via gravity into the lateral ventricle. When cannula 
placement could not be confirmed, mice were excluded from the study. All procedures 
were in accordance with the National Institutes of Health Guidelines for the Care and 
Use of Laboratory Animals and were approved by the University of Illinois Institutional 
Animal Care and Use Committee. 
 
117 
 
Experimental protocols 
Mice were handled 1-2 minutes (min) each day for 7 days before experimentation 
to acclimate them to handling. To assess the effects of LPS on STAT3 phosphorylation 
in the hippocampus as well as IL-6 in the hippocampus mice were injected i.p. with 
sterile saline or 0.33 mg/kg BW (10 µg) LPS (serotype 0127:B8, obtained from Sigma, 
St. Louis, MO) and killed by CO2 asphyxiation 1, 2, 4, 6, or 8 h later.  Blood samples 
were collected via cardiac puncture into EDTA-coated syringes to obtain plasma, and 
the brain was rapidly removed and dissected to obtain hippocampal tissue. Plasma and 
hippocampal tissue were snap frozen in liquid nitrogen and stored at -80o C for later 
analysis.  To assess the role of IL-6 trans-signaling mice were injected icv with sterile 
saline containing 0.1% BSA (vehicle) or 100 ng sgp130 (R&D systems, Minneapolis, 
MN) in 2 µl vehicle and then i.p. with sterile saline or 0.33 mg/kg BW (10 µg) LPS. In 
some cases mice were killed to obtain hippocampal tissue as described above.  In other 
cases, mice were evaluated in a contextual fear conditioning paradigm to assess 
hippocampal-dependent learning and memory.    
Western immunoblotting  
To assess IL-6 signaling, hippocampal tissue was unthawed, and lysed in ice 
cold lysis buffer containing: 100 mM HEPES (7.5 pH), 150 mM NaCl, 1% nonidet P-40 
(U.S. Biological, Swampscott, MA), 2 mM EGTA, 2 mM sodium orthovanadate, protease 
inhibitor cocktail (10 0mM EDTA, 1 µg/mL AEBSF, bestatin, pepstatin A, leupeptin, 
aprotinin, and E-64), and 1 mM PMSF, and centrifuged at 11,000 × g for 10 min at 4oC 
to remove all cellular debris. Protein concentration was determined using the BCA 
Protein Assay according to the manufacturer’s protocol (Bio-Rad, Hercules, CA). Lysate 
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concentration was then normalized and denatured in SDS/PAGE buffer at 95oC and 
stored at -20oC until use. All lysates were electrophoresed and separated on a 7.5% 
SDS-PAGE gel, and transferred onto nitrocellulose membranes (GE Healthcare, 
Minneapolis, MN). The membranes were blocked with 5% non-fat milk and incubated 
with anti-phosphorylated STAT3 (tyr-705) antibody (Cell Signaling, Danvers, MA) 
overnight at 4°C. After incubation with an HRP-conjugated secondary antibody, the 
protein bands were detected with a chemiluminescent substrate (Cell Signaling, 
Danvers, MA) and Bio-Max film (Eastman Kodak Company, Rochester, NY). For 
detection of total STAT3 protein, the membranes were stripped with stripping buffer (2% 
SDS, 6.25 mM Tris.HCL [6.8 pH], 0.704% β-ME), followed by overnight incubation with 
anti-STAT3 antibody (Cell Signaling, Danvers, MA) at 4°C. The phosphorylated STAT3 
protein has an alpha and beta isoform which are expressed in two bands at 86 and 
79kDa, respectively. Upon activation, the alpha isoform (86-kDa) is the principal isoform 
that is phosphorylated and the beta isoform (79-kDa) represents a point of maximal 
STAT3 activation. The area where both bands are located were quantified using ImageJ 
1.41 software (NIH). 
Interleukin-6 mRNA measurement by quantitative real-time PCR 
Total RNA from hippocampal tissue was isolated using the Tri Reagent protocol 
(Sigma, St. Louis, MO). A QuantiTect Reverse Transcription Kit (Qiagen, Valencia, CA) 
was used for cDNA synthesis with integrated removal of genomic DNA contamination 
according to the manufacturer’s protocol. Quantitative real-time PCR was performed 
using the Applied Biosystems (Foster, CA) Assay-on Demand Gene Expression 
protocol as previously described (Krzyszton et al., 2008). In brief, cDNA was amplified 
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by PCR where a target cDNA (IL-6, Mm00446190_m1; and a reference cDNA (glucose-
3 phosphate dehydrogenase, Mm99999915_g1) were amplified simultaneously using 
an oligonucleotide probe with a 5’ fluorescent reporter dye (6-FAM) and a 3’ quencher 
dye (NFQ). PCR reactions were performed in triplicate under the following conditions: 
50oC for 2 min, 95oC for 10 min, followed by 40 cycles of 95oC for 15 sec, and 60oC for 
1 min. Fluorescence was determined on an ABI PRISM 7900HT-sequence detection 
system (Perkin Elmer, Forest City, CA). Data were analyzed using the comparative 
threshold cycle (Ct) method, and results are expressed as fold difference. 
 
Interleukin-6 detection in hippocampus and plasma 
 Hippocampal tissue was lysed in ice cold lysis buffer and protein concentrations 
were determined using the BCA protein assay according to manufacturer’s protocol. 
The antibodies and standards for the IL-6 ELISA were used according to the description 
by the manufacturer (eBiosciences San Diego, CA). Plasma samples were assayed for 
IL-6 using a bead-based immunoassay kit combined with a Cytokine Reagent kit, as 
described by the manufacturer (Bio-Rad, Hercules, CA).  
Contextual fear conditioning 
A contextual fear conditioning paradigm was used as described previously with 
few modifications (Peleg et al., 2010). The fear conditioning apparatus consisted of an 
opaque conditioning cage (30 × 30 × 30 cm) with a transparent ceiling to permit video 
recording by an overhead camera.  The floor consisted of a series of stainless steel 
rods wired to a shock generator and scrambler (ENV-414S, MED Associates, St. 
Albans, VT). On acquisition day, mice were placed in the cage for 120 s, followed by a 
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2-s foot-shock (0.75 mA); this time interval was repeated and 30 s after the delivery of 
the second shock mice were co-administered saline or sgp130 icv and saline or LPS i.p. 
To test the hippocampal-dependent contextual fear conditioning, 48 h after acquisition 
mice were placed in the original conditioning cage for the time equal to that in 
acquisition (4 min and 30 s). A trained observer who was blind to experimental 
treatments scored the fearful experience by a continuous measurement of freezing 
(complete immobility), the dominant fear behavioral response (Fanselow, 2000). In 
interpreting data from the fear conditioning paradigm, an increase in freezing in the 
retention phase (conducted 48 h after acquisition) indicates an improvement in learning.  
Statistical analysis 
All data were analyzed using the ANOVA routine in Statview and MIXED 
procedure of the Statistical Analysis System software (SAS Inst., Cary, NC). Data were 
subjected to a univariate analysis to ensure normality. In the time course and knockout 
study, STAT3 phosphorylation, IL-6 mRNA and protein were subjected to a two-way 
ANOVA in which age (adult or aged) and LPS (sterile saline or 10 µg) were between 
subject measures. Percent freezing on retention day, IL-6 protein levels, and STAT3 
phosphorylation were subjected to a two-way ANOVA in which sgp130 (vehicle or 100 
ng), and LPS (sterile saline or 10 µg) were between subject measures. When 
appropriate, data from individual time points were subjected to ANOVA to determine 
treatment effects. Post hoc Student’s t test of least square means was used to 
determine if treatment means were significantly different from one another (p<0.05). All 
data are presented as mean ± standard error of the mean (SEM). 
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5.4 Results 
 LPS-induced STAT3 phosphorylation is increased in hippocampus of aged mice 
As a read out for IL-6 signaling, STAT3 phosphorylation was determined in the 
hippocampus of adult and aged mice after i.p. injection of LPS. Figure 5.1 shows 
representative western blots revealing phosphorylated STAT3 in hippocampi collected 
from adult and aged mice at various times after injection of LPS and the mean STAT3 
phosphorylation from 8 or 9 treatment replicates at each time point for each age.  As 
expected STAT3 activity in the hippocampus was increased 1 h after LPS in both adult 
and aged animals.  However, whereas the level of STAT3 phosphorylation reached a 
plateau by 1 h in adults, it continued to increase in the aged.  An age × LPS interaction 
at 4 h (p<0.05) and at 6 h (p<0.01) indicated a marked increase in STAT3 activity in the 
hippocampus of aged mice. As we surmised that increased IL-6 was responsible for the 
increased STAT3 activity, plasma IL-6 and IL-6 mRNA in the hippocampus were 
measured in adult and aged mice 6 h after LPS injection when STAT3 phosphorylation 
was maximal in the aged. As evident in Figure 5.2, before or after LPS injection, plasma 
IL-6 (Figure 5.2A) and hippocampal IL-6 mRNA (Figure 5.2B) were markedly higher in 
aged mice compared to adults.  Collectively, these data show a close association 
between increased levels of IL-6 and IL-6 signaling during times of peak sickness in the 
hippocampus of senescent mice. To confirm that IL-6 was responsible for the increased 
STAT3 activity, a subsequent study was conducted using adult and aged IL-6+/+ and IL-
6-/- mice. Figure 5.3 shows representative western blots revealing phosphorylated 
STAT3 in hippocampi collected from adult and aged IL-6+/+ and IL-6-/- mice 6 h after 
injection of LPS and the mean STAT3 phosphorylation from 6 or 7 treatment replicates.  
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Despite employing a different genetic background than in the first study (C57BL/6 vs. 
BALB/c), once again hippocampal STAT3 phosphorylation was significantly increased in 
aged IL-6+/+ mice compared to adult IL-6+/+ mice (p<0.05) after LPS injection (Figure 
5.3B).  Importantly, the LPS-induced increase in STAT3 activity was ablated in IL-6-/- 
mice (Figure 5.3B), suggesting IL-6 is a key driver of STAT3 activity in the aged brain 
after peripheral immune stimulation.        
IL-6 trans-signaling induces STAT3 activity in hippocampus of aged mice  
To determine if the age-related increase in hippocampal STAT3 activity after LPS 
injection was mediated by IL-6 via the classical or trans-signaling pathway, aged 
BALB/c mice were surgically fit with an indwelling icv cannula. Following recovery, mice 
were injected icv with sgp130 and i.p. with LPS.  Similar to earlier results, LPS up 
regulated STAT3 phospho-protein and IL-6 in the hippocampus (Figures 5.4 and 5.5, 
respectively). Furthermore, there was a sgp130 × LPS interaction where both LPS-
induced IL-6 (p<0.04) and STAT3 activity (p<0.05) in the hippocampus, was markedly 
reduced by sgp130.  LPS is a potent activator of IL-6 and the positive feedback loop 
which induces optimal expression of STAT3 in the vehicle/LPS treated group, but this 
expression is ameliorated in sgp130/LPS treated animals. As sgp130 binds IL-6 that is 
coupled with sIL-6R preventing it from activating membrane bound gp130 (Barkhausen 
et al., 2011), these data suggest a key role for IL-6 trans-signaling in the hippocampus.   
sgp130 inhibits LPS-induced deficits in contextual fear conditioning 
Circulating IL-6 and cognitive dysfunction are positively correlated (Bellinger et 
al., 1995; Gruol and Nelson, 1997; Maggio et al., 2006; Weaver et al., 2002), and acute 
cognitive disorders are common in elderly patients during peripheral infection.  Thus, we 
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were eager to know if inhibiting IL-6 trans-signaling would protect aged mice from LPS-
induced deficits in cognition.  Aged BALB/c mice were injected icv with sgp130 and i.p. 
with LPS immediately after the acquisition phase of contextual fear conditioning.  Forty-
eight hours later their freezing response in the retention phase was assessed.  As 
evident in Figure 5.6, LPS reduced immobility in aged mice, indicating immune 
activation interfered with memory consolidation.  However, icv injection of sgp130 which 
reduced STAT3 activation and IL-6 in the hippocampus completely blocked the deficit in 
hippocampal-based contextual fear conditioning caused by LPS.  
 
5.5 Discussion 
 
Excessive production of pro-inflammatory cytokines in the senescent brain in 
response to peripheral immune stimulation (Godbout and Johnson, 2009) is thought to 
induce behavioral pathology and be a forerunner to neurodegenerative disease.  
However, few studies have examined if the increase in pro-inflammatory cytokines is 
accompanied by an increase in cytokine signaling, which would be a prerequisite if the 
behavioral changes are driven by the pro-inflammatory cytokine response. By focusing 
on IL-6 as a prototypical pro-inflammatory cytokine, the present results show that the 
magnitude and duration of IL-6 signaling are increased in the hippocampus of 
senescent mice compared to adults after peripheral injection of LPS.  They further 
suggest a key role for IL-6 trans-signaling in hippocampal dysfunction in the senescent 
and highlight the potential value of sgp130 for preventing infection-related behavioral 
pathology.   
In the present study, STAT3 phosphorylation was used as an indicator of IL-6 
signaling.  Both classical and trans-signaling pathways cause gp130 to dimerize, 
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resulting in an intracellular cascade that recruits and phosphorylates STAT3.  Although 
other cytokines that were previously detected in the CNS also activate STAT3 (e.g., IL-
10), the fact that STAT3 activation was not increased after LPS injection in aged IL-6-/- 
mice strongly suggests the increased STAT3 phosphorylation in aged wild type mice 
was due to IL-6. This is further supported by the fact that IL-6 mRNA and protein were 
markedly higher in the hippocampus of aged mice compared to adults at the time 
corresponding to maximal STAT3 phosphorylation.  However, it should be noted that 
other cytokines that can activate STAT3 were not measured in this study.  Due to the 
fact that sgp130 binds the IL-6-sIL-6R complex in the extracellular matrix and prevents it 
from activating membrane bound gp130, it is a naturally occurring antagonist of the IL-6 
trans-signaling pathway (Jostock et al., 2001).  Since it has a low affinity for IL-6 that is 
unbound to sIL-6R, sgp130 does not interfere with IL-6R signaling (Jones et al., 2005; 
Muller-Newen et al., 1998). Therefore, sgp130 can be used to elucidate the contribution 
of the IL-6 trans-signaling pathway to biologically relevant outcomes.  For example, 
sgp130 was recently reported to reduce LPS-induced sickness behavior in mice (Burton 
et al., 2011).  The finding that LPS-induced sickness was mediated by the trans-
signaling pathway and not the classical pathway was consistent with the finding that 
Neuro.2A cells (a neuronal cell line) expressed abundant levels of gp130 but very little 
IL-6R (Burton et al., 2011).  If neurons express few IL-6R but are laden with gp130 and 
mostly influenced by IL-6 through the trans-signaling pathway, this would explain earlier 
work that found recombinant IL-6 had little effect on behavior when injected icv but 
induced profound sickness when co-administered with sIL-6R (Schobitz et al., 1995).  In 
the present study sgp130 given icv reduced LPS-induced STAT3 activity in the 
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hippocampus of aged mice, further highlighting the importance of IL-6 trans-signaling in 
the brain. These findings regarding IL-6 trans-signaling in the brain are consistent with a 
recent study of IL-6 trans-signaling and TLR4-driven inflammatory responses in the 
periphery (Greenhill et al., 2011).  Cross-talk between JAK/STAT and TLR4 pathways is 
now viewed as a broad-based mechanism that regulates the severity of inflammation.  
Other studies suggest inhibiting IL-6 trans-signaling with sgp130 may be helpful in 
treating a number of inflammatory conditions including arthritis, peritonitis, and colitis 
(Coles et al., 2007; McLoughlin et al., 2005; Richards et al., 2006).   
Activated STAT3 translocates to the nucleus where it binds to enhancer 
elements of the IL-6 gene to induce transcription. Thus, a primary effect of IL-6 is to 
induce expression of more IL-6 (Aaronson and Horvath, 2002).  Other IL-6 family 
members (LIF, OSM, IL-11) as well as IL-10 and interferons activate STAT3, albeit, to a 
lesser degree, and evidence from this (Figure 3) and other studies, show that in IL-6 is 
the most potent activator of STAT3 (Bluthe et al., 2000).  Although our goal was to 
investigate IL-6 signaling in the senescent brain as opposed to mechanisms responsible 
for the exaggerated production of the cytokine, the present study suggests the 
involvement of a positive feedback loop initiated through trans-signaling where IL-6 
begets IL-6. This is best exemplified in Figure 5.5 where sgp130 given icv is shown to 
reduce LPS-induced IL-6 in the hippocampus by about half.       
Due to the fact that sgp130 reduced STAT3 activity and IL-6 levels in the 
hippocampus, it was reasonable to postulate that it would also inhibit LPS-induced 
deficits in hippocampal-dependent learning and memory.  Therefore, we chose to focus 
on hippocampal-dependent context conditioning since it has been shown that the 
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hippocampus is greatly affected in aging. This is important because immune stimuli are 
known to inhibit consolidation of memories in hippocampal-dependent tasks (Pugh, 
2001; Pugh et al., 1998), and hippocampal-dependent tasks are more easily disrupted 
in aged animals compared to adults (Adams et al., 2001; Barrientos et al., 2006; 
Bruunsgaard et al., 2001; Chen et al., 2008; Cortese et al., 2011)  In the present study, 
aged mice given LPS after the acquisition phase showed less immobility when 
reintroduced to the environment where they experienced mild shock, meaning they 
were less effective at establishing an association between the environment and noxious 
stimulus, which could be dangerous in a natural setting.  However, treatment with 
sgp130 completely blocked this effect of LPS, suggesting IL-6 trans-signaling is 
involved in infection-related hippocampal dysfunction.  Consistent with previous studies, 
results with adult animals showed context conditioning was impaired by post-training 
LPS, although the age × treatment interaction did not reach significance (data not 
shown).  This phenomenon is potentially due to the single point in time of testing, which 
was not broad enough to reveal differences.  
Ongoing studies are underway to identify the cell type(s) in the brain that are 
responsible, and the mechanisms behind this IL-6 trans-signaling -mediated response 
to LPS during aging; proposed mechanisms are modulation of the blood-brain barrier, 
chemokine activation, and oxidative stress. It is interesting that blocking trans-signaling 
was sufficient to protect contextual fear conditioning since other pro-inflammatory 
cytokines such as IL-1β are known to inhibit hippocampal-dependent learning and 
memory during infection (Yirmiya et al., 2002), but signal through different pathways.  
However, we previously showed that mice deficient in IL-6 (i.e., IL-6-/- mice) also had 
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reduced levels of IL-1β and TNFα in the hippocampus after peripheral LPS challenge, 
suggesting IL-6 plays a permissive role in the production and/or activities of other pro-
inflammatory cytokines (Sparkman et al., 2006). This is consistent with a recent study 
by Greenhill et al. (2011) that suggested IL-6 trans-signaling is an important determinant 
in TLR4-driven inflammation.  Taken together, the present study suggests that sgp130 
may be useful for protecting against infection-related neuroinflammation and cognitive 
dysfunction in the aged.   
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5.6 Figures 
 
 
Figure 5.1: Activated STAT3 in the hippocampus of adult and aged mice after peripheral 
injection of LPS. Adult and aged BALB/c mice were injected i.p. with LPS and hippocampal 
tissue was collected at various time points after injection to measure phosphorylated STAT3.  
The upper panel shows representative western blots and the bar graph shows mean STAT3 
phosphorylation (± SEM) from 8-9 treatment replicates at each time point for each age (because 
STAT3 activity was not affected in saline controls over time, data from saline treated mice at 
different time points was pooled. Means with different letters are significantly different (p<0.05). 
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Figure 5.2:  Plasma IL-6 and IL-6 mRNA in the hippocampus in aged and adult mice 6 h 
after LPS injection.  Adult and aged BALB/c mice were injected i.p. with LPS and 6 h later, 
blood and brain tissue were collected for analysis. Bars represent the mean ± SEM (n = 7-8). 
Means with different letters are significantly different (p<0.05). 
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Figure 5.3: Phosphorylated STAT3 in hippocampus of adult and aged IL6+/+ and IL-6-/- 
mice after injection of LPS. Adult and aged IL-6+/+ and IL-6-/- mice were injected i.p. with LPS 
and hippocampal tissue was collected to measure phosphorylated STAT3.  The upper panel 
shows representative western blots and the bar graph shows mean STAT3 phosphorylation (± 
SEM) from 6-7 treatment replicates. Means with different letters are significantly different 
(p<0.05). 
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Figure 5.4: Effects of sgp130 on LPS-induced STAT3 activity in the hippocampus of aged 
mice. Aged BALB/c mice were injected icv with sgp130 and i.p. with LPS and hippocampal 
tissue was collected 6 h later.  The upper panel shows representative western blots and the bar 
graph shows mean STAT3 phosphorylation (± SEM) from 8-9 treatment replicates. Means with 
different letters are significantly different (p<0.05). 
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Figure 5.5: Effects of sgp130 on LPS-induced IL-6 in the hippocampus of aged mice. 
Aged BALB/c mice were injected icv with sgp130 and i.p. with LPS and hippocampal tissue was 
collected 6 h later for determination of IL-6.  The bar graph shows mean IL-6 concentration (± 
SEM) from 8-9 treatment replicates. Means with different letters are significantly different 
(p<0.05). 
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Figure 5.6: Effects of sgp130 on the LPS-induced deficit in contextual fear conditioning in 
aged mice. Aged BALB/c mice were injected icv with sgp130 and i.p. with LPS immediately 
after the acquisition phase of contextual fear conditioning.  Forty-eight hours later immobility in 
the retention phase was assessed. Bars represent the mean ± SEM (n = 12-15). Means with 
different letters are significantly different (p < 0.05). 
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Chapter 6 
The selective blockade of the interleukin-6 trans-signaling pathway prevents LPS-
induced sickness and microglia hyperactivity in the aged 
 
 
6.1 Abstract  
During systemic infection, inflammatory cytokines such as interleukin (IL)-6 are 
excessively produced in the brain of aged animals and induce infection-related 
behavioral deficits. However, no studies have examined how pro-inflammatory IL-6 
trans-signaling on specific cell types is involved in the exaggerated production of IL-6 in 
the aged brain. Nor the extent to which IL-6 trans-signaling affects other markers of 
neuroinflammation, oxidative stress, adhesion molecules, and behavioral 
consequences. Therefore, this study investigated the presence of IL-6 signaling 
subunits, the central effects of soluble gp130 (sgp130), a natural inhibitor of the IL-6 
trans-signaling pathway, on IL-6 production in microglia and astrocytes of senescent 
mice, as well as its effects on lipopolysaccharide (LPS)-induced neuroinflammation and 
behavioral deficits. Here we show that aged microglia have higher surface expression of 
IL-6 receptor (IL-6R) as well as higher hippocampal gene expression of ADAM17, the 
enzyme responsible for shedding membrane-bound IL-6R in trans-signaling.  
Additionally, we show that peripheral LPS challenge elicits a hyperactive IL-6 response 
in both microglia and astrocytes and selective blockade of trans-signaling with sgp130 
mitigates the exaggerated levels of IL-6 in both microglia and astrocytes. This sgp130-
associated inhibition of IL-6 was paralleled by amelioration of the exaggerated and 
protracted sickness behavior observed in aged animals. Taken together, the results 
show that microglia and astrocytes are important regulators of the IL-6 trans-signaling 
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response in the aged brain and sgp130 exerts an anti-inflammatory effect by inhibiting 
the pro-inflammatory arm of IL-6 signaling.  
6.2 Introduction 
Immune-to-brain communication is important for the appropriate physiological 
and behavioral response to immune stimuli (Dantzer et al., 1998); this activation 
stimulates the production of pro-inflammatory cytokines in the central nervous system 
(Quan, 2008).  These pro-inflammatory cytokines are produced by microglia, which are 
highly dynamic resident macrophages of the brain that are closely associated with 
astrocytes and neurons (Block et al., 2007). The resulting cytokine production from 
microglia target neurons to elicit sickness-related behaviors that are adaptive (Kelley et 
al., 2003).  
In aging, this adaptive physiological response becomes maladaptive as there is 
excessive cytokine production in the brain in response to a peripheral immune stimulus 
(Godbout et al., 2005b). The exaggerated production of cytokines are associated with 
behavioral deficits, such as exaggerated sickness behaviors (Abraham and Johnson, 
2009a; Godbout et al., 2005b; Huang et al., 2008) and cognitive deficits (Chen et al., 
2008). Microglia appear to be the principal cell type responsible for this aberrant 
cytokine production, as there is a sizeable primed population of microglia seen in the 
aged (Henry et al., 2009). It is possible that primed microglia play an integral role in 
mediating a hostile microenvironment that greatly affects astrocyte and neuronal 
function.  
Interleukin-6 production in the CNS has various effects, and evidence suggests it 
plays a crucial role as a mediator of sickness amongst other behaviors. Studies with IL-
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6-deficient animals have implicated that IL-6 production in the hypothalamus is involved 
in the fever response (Rummel et al., 2006), multiple studies have shown IL-6-deficient 
animals are resistant to peripheral immune stimulated sickness behaviors (Burton, 2012 
; Nguyen et al., 2011), as well as refractory to LPS-induced deficits in working memory 
(Sparkman et al., 2006). Moreover, we have recently shown that IL-6 trans-signaling in 
the brain plays a pivotal role in mediating recovery from LPS-induced sickness in adults 
(Burton et al., 2011). Other studies have supported the notion that IL-6 trans-signaling is 
specifically involved in the pro-inflammatory arm while classic signaling is typically anti-
inflammatory or regenerative in nature (Greenhill et al., 2011; Rose-John et al., 2007). 
While transgenic studies that completely ablate the function of IL-6 gives evidence to its 
action; we feel it is necessary to develop studies that focus on directly inhibiting the 
individual signaling pathways, which allows a way to tease out the beneficial functions 
from the detrimental functions. 
 IL-6 receptor signaling is facilitated through two related pathways termed 
classical and trans-signaling. The receptor consists of two subunits: the IL-6 receptor-
alpha chain (IL-6R), which binds IL-6, and the transmembrane signaling subunit, 
glycoprotein 130 (gp130), which is the intracellular signal transducer that is 
constitutively expressed. Classical activation consists of the IL-6 ligand binding to the 
membrane-bound IL-6R, while trans-signaling is the ability of a soluble IL-6R (sIL-6R) to 
bind IL-6 ligand in the extracellular compartment to form an IL-6/sIL-6R complex. 
Importantly, the expression pattern of membrane-bound IL-6R is limited to cells of the 
immune system and sparsely dispersed among other cell types, while gp130 is 
ubiquitously expressed;  therefore IL-6 trans-signaling confers IL-6 responsiveness in 
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any cell type that expresses gp130 (Jones et al., 2005; Kishimoto et al., 1992; Rose-
John and Heinrich, 1994).   
Both receptor subunits (IL-6R and gp130) are cleaved immediately before the 
membrane spanning region by alternative splicing or shed by proteolytic enzymes to 
produce a soluble receptor located in extracellular matrix. While alternative splicing 
plays a significant role in soluble gp130 (sgp130), it has a much smaller role in the 
production of sIL-6R. Recent studies on monocytes and other cell lines have shown that 
two specific members of the a disintegrin and metalloproteinase domain (ADAM) ADAM 
family of zinc-dependent metalloproteinases, ADAM17 and ADAM10, contribute to the 
leading mechanism IL-6R shedding to sIL-6R (Matthews et al., 2003) 
 sIL-6R and sgp130 have varying effects on circulating IL-6. sgp130 acts as an 
antagonist to the IL-6/sIL-6R complex and prevents the binding of membrane-bound 
gp130 and further signal transduction (Jostock et al., 2001). Upon binding through either 
the classical or trans-signaling pathway, gp130 dimerizes and autophosphorylates, 
resulting in the activation of downstream signaling molecules, Janus kinase-1 and 2 
(Jak1 and Jak2) and signal transducer and activation of transcription-3 (STAT3). Once 
STAT3 is activated, it is translocated to the nucleus and binds to enhancer elements of 
the IL-6 promoter region. It is important to note negative transcriptional regulators of 
STAT3 activation or suppressors of cytokine signaling (SOCS) proteins 1 and 3 that are 
present to prevent or curb STAT3 translocation to the nucleus and prevent cytokine-
induced signaling. 
In recent studies that have begun to tease out the anti- versus pro-inflammatory 
actions of IL-6, the trans-signaling mechanism exhibits its pro-inflammatory actions by 
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eliciting the production of IL-6 by non-immune cells, which in turn recruit immune cells to 
the site (Barkhausen et al., 2011; Greenhill et al., 2011; Scheller et al., 2011). The 
action of IL-6 is heavily dependent on the location of the receptors and the cell types 
exposed to the cytokine. In the CNS, it has been shown that neurons do not express 
considerable amounts of IL-6R, however, they do express large amounts of gp130 
(Burton et al., 2011; Schobitz et al., 1993), alluding to the importance of IL-6 trans-
signaling and pro-inflammatory processes in the brain. In aging, our lab has shown that 
IL-6 is basally upregulated and that microglia are the main cell type responsible for this 
upregulation (Godbout and Johnson, 2004; Ye and Johnson, 1999b, 2001) . However, 
how microglia interact with other cells of the CNS and the mechanism of this 
upregulation is not clearly defined. 
In a neurodegenerative model for multiple sclerosis, Linker et., al. found that IL-6 
trans-signaling modulated the blood brain barrier (BBB), T-cell infiltration and adhesion 
molecules ICAM-1 and VCAM-1 (Linker et al., 2008), all of which are regulated by 
astrocytes. Astrocytes are also recognized as a major inducible source of IL-6, however 
very few studies have focused on astrocytes to ascertain their role in the exaggerated 
production of IL-6 in aging. 
To our knowledge, there are few studies that begin to examine the extent to 
which peripheral infection influences IL-6 trans-signaling, neuroinflammation, and 
infection-related changes in behavior in the aged brain. Based on data obtained from a 
previous study (Burton et al., 2011), we believed it was possible that sgp130 would 
abrogate the exaggerated and prolonged LPS-induced alterations in sickness behavior 
as well as exaggerated IL-6 levels in aged mice. 
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The present study investigated cell-specific machinery important for IL-6 
activation in adult and aged brain as well as gene expression in the hippocampus, to 
elude the self-perpetuating mechanism of exaggerated IL-6 production in the aged 
brain. Further studies assessed the extent to which sgp130 was able to mitigate 
exaggerated LPS-induced IL-6 production in microglia and astrocytes, as well as 
augment behavioral deficits in aged mice. Our data show that intracerebroventricular 
(icv) sgp130 inhibited the onset of sickness behavior, which was paralleled by a 
decrease in LPS-induced IL-6 gene expression in the hippocampus of sgp130-treated 
mice. These findings suggest that inhibition of excessive production of IL-6 through its 
trans-signaling pathways during peripheral infection is crucial in preventing behavioral 
deficits in aged mice. 
6.3 Materials and Methods 
Animals and Surgery 
Adult (3-6 months) and aged (22-24 months) male BALB/c mice were obtained 
from our in-house breeding colony. The median life span for BALB/c mice is 
approximately 26 months (Morley and Trainor, 2001), and therefore 3- to 6-month-old 
(adult) and 20- to 24-month-old (aged) male mice were used. Mice were housed in 
polypropylene cages and maintained at 21°C under a reverse-phase 12 hour (h) light-
dark cycle with ad libitum access to water and rodent chow. At the end of each study, 
mice were examined post mortem for gross signs of disease (e.g., tumors or 
splenomegaly). Data from mice determined to be unhealthy were excluded from the 
analysis (< 5%). 
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Surgery: icv cannulation was performed under aseptic conditions as described 
previously (Abraham et al., 2008). In brief, mice were deeply anesthetized with an 
intraperitoneal (i.p.) injection of ketamine and xylazine (100 and 10 mg/kg, respectively) 
and the surgical site was shaved and sterilized. They were positioned in a stereotaxic 
instrument (David Kopf Instruments, Tujunga, CA) so that the frontal and parietal bones 
of the skull were parallel to the surgical platform. An incision roughly 1.5 cm in length 
was made on the cranium to reveal the bregma and a 26-gauge stainless steel cannula 
(Plastics One, Roanoke, VA) was placed in the right lateral cerebral ventricle according 
to predetermined stereotaxic coordinates (lateral 1.6 mm and antero-posterior 1 mm to 
the bregma, and horizontal 2 mm from the dura mater). The cannula was secured using 
two adjacent stainless steel screws and cranioplastic cement (Plastics One, Roanoke, 
VA). A dummy cannula (Plastics One, Roanoke, VA) was inserted in the guide cannula 
to prevent occlusion and infection. Mice were injected subcutaneously with 
buprenorphine (0.05 mg/kg) following surgery and then again 8–12 h later to aid with 
any post-operative discomfort. Mice were provided a minimum of 7 days to recover 
before any treatment or behavioral test. Accurate placement of the cannula was 
confirmed by allowing 2 µl of sterile saline to flow via gravity into the lateral ventricle. If 
cannula placement could not be confirmed by gravity flow the animal was excluded from 
the study. All procedures were in accordance with the National Institutes of Health 
Guidelines for the Care and Use of Laboratory Animals and were approved by the 
University of Illinois Institutional Animal Care and Use Committee. 
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Experimental protocols 
Mice were routinely handled 1-2 minutes (min) each day for 7 days before 
experimentation to acclimate them to handling. Animals were injected icv with sterile 
saline containing 0.1% BSA (vehicle) or 100 ng sgp130 (R&D systems, Minneapolis, 
MN) dissolved in 2 µl vehicle. At the same time as the icv injection of sgp130, mice were 
injected i.p. with sterile saline or 0.33 mg/kg BW (10 µg) LPS (serotype 0127:B8, 
obtained from Sigma, St. Louis, MO).  
To measure changes in cytokines, mice not exposed to the behavior paradigms 
were injected icv with vehicle or sgp130 (100 ng) and i.p. with vehicle or LPS (10 µg), 
and killed 6 h or 24 h later by CO2 asphyxiation.  The brain was rapidly removed and 
dissected to obtain hippocampal tissue which was snap frozen in liquid nitrogen and 
stored at -80oC until later analysis.   
Behavioral tests 
Locomotor activity: Mice were maintained in their home cage and locomotor 
activity was video recorded during 5 min intervals using a camera mounted 
approximately 91.0 cm directly above the center of the cage floor. Behavioral tests were 
conducted on icv sgp130- and i.p. LPS-treated animals during the dark phase (between 
07:00 and 19:00) of the light/dark cycle under infrared lighting to aid video recording. 
Baseline behavior was taken just before treatment (0 h) and behavior was recorded 4, 
6, 8, and 24 h after administration of sgp130 (0 ng or 100 ng icv) and LPS (0 µg or 10µg 
i.p.). Videos were tracked to by Ethovision (Noldus, Leesburg, VA) software, to record 
total distance moved. Body weight and food intake were measured at each time point 
over the 24-h period.  
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Microglia and Astrocyte isolation 
In experiments for flow cytometry, microglia and astrocytes from whole brain 
were isolated as described previously, with few modifications (Cardona et al., 2006; 
Henry et al., 2009). Mice were euthanized by CO2 asphyxiation and whole brains were 
collected and stored in sterile PBS. Brains were homogenized by passage through a 70 
µm cell strainer in Dulbecco’s Phosphate Buffered Salt Solution (DPBS) supplemented 
with 0.2% glucose. Resulting homogenates were centrifuged at 600 × g for 6 min at 
10oC. Supernatants were removed and cell pellets were re-suspended in a 70% isotonic 
Percoll (GE-healthcare, Uppsala, Sweden) supplemented with phenol red (0.01%) at 
room temperature. A discontinuous Percoll density gradient of 70%, 50%, 35%, and 0% 
isotonic Percoll was set up. The gradient was centrifuged for 20 min at 2000 × g and 
microglia were collected from the interphase between the 70% and 50% Percoll layers 
(Frank et al., 2006), while astrocytes were collected from the interphase between the 
50% and 35% Percoll layers (Kozlova and Takenaga, 2005; Park et al., 2012). Cells 
were washed with DPBS and then re-suspended in PBS- 0.5% BSA/ 0.01% sodium 
azide solution (flow buffer). The number of viable cells was determined using a 
hemacytometer and 0.1% trypan blue staining; each isolation yielded approximately 3 
×105 viable microglia and 4×106 viable astrocytes. 
Extracellular and intracellular flow cytometric analysis 
Flow cytometric analysis of microglial surface and intracellular markers was 
performed based on BD Cytofix/Cytoperm Plus fixation/permeabilization protocol (BD 
biosciences, CA), as described previously, with a few modifications (Henry et al., 2009). 
In brief, cells isolated by Percoll density gradient were incubated in DMEM (Bio-
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Whittaker, Cambrex, MD) supplemented with 10% FBS (Hyclone, Logan, UT), 200 mM 
glutamine, and 100 units/ml penicillin/streptomycin (Invitrogen, Carlsbad, CA), and a 
solution containing brefeldin A (BD Biosciences, CA) at 37°C in a humidified incubator 
under 5% CO2, for 4 h.  Cells were then washed in flow buffer and Fc receptors were 
blocked with anti-CD16/CD32 antibody (eBioscience, CA). Microglia were first incubated 
with surface markers, anti-CD11b-Allophycocyanin (APC), anti-CD45-Fluorescein 
isothiocynate (FITC), and anti-MHC-II-Phycoerythrin (PE) antibodies (eBioscience, CA). 
Next, both microglia and astrocytes cells were fixed and permeabilized with BD 
Cytofix/CytopermTM solution for 20 min. Cells were washed with BD Perm/WashTM 
buffer, re-suspended in BD Perm/WashTM buffer, astrocytes were incubated with anti-
GFAP-Alexa Fluor 488 and anti-IL-6 PE, and microglia were incubated with anti-IL-6-PE 
(eBioscience, CA) for 30 min. Cells were washed twice in BD Perm/WashTM buffer and 
re-suspended in flow buffer. Expression of surface and intracellular antigens was 
determined using a Becton-Dickinson LSR II Flow Cytometer (Red Oaks, CA). Thirty 
thousand events were collected, microglia were identified by CD11b+ and CD45+low 
expression (Ford et al., 1995) and astrocytes were identified by GFAP+ expression (Raff 
et al., 1979). Gating was determined based on fluorescently labeled isotype antibodies 
for PE, FITC, Alexa Fluor 488, and APC (eBioscience, San Diego, CA), and unstained 
samples as controls. Flow data were analyzed using FCS Express software (De Novo 
Software, Los Angeles, CA).  
Cytokine mRNA measurement by quantitative real-time PCR 
Total RNA from hippocampal tissue was isolated using the Tri Reagent protocol 
(Sigma, St. Louis, MO) A QuantiTect Reverse Transcription Kit (Qiagen, Valencia, CA) 
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was used for cDNA synthesis with integrated removal of genomic DNA contamination 
according to the manufacturer’s protocol. Quantitative real-time PCR was performed 
using the Applied Biosystems (Foster, CA) Assay-on Demand Gene Expression 
protocol as previously described (Krzyszton et al., 2008). In brief, cDNA was amplified 
by PCR where a target cDNA (IL-6, Mm00446190_m1;IL-6Rα, Mm00439653_m1; IL-
1β, Mm00434228_m1; TNF-α, Mm00443258_m1; IL-10, Mm00439616_m1, ADAM10 
Mm00545742_m1; ADAM17 Mm00456428_m1; Icam Mm00516023_m1; Vcam 
Mm01320970_m1;  Socs1Mm00782550_s1;  Socs3 Mm00545913_s1; iNOS2 
Mm01309902; and a reference cDNA (glucose-3 phosphate dehydrogenase, 
Mm99999915_g1) were amplified simultaneously using an oligonucleotide probe with a 
5’ fluorescent reporter dye (6-FAM) and a 3’ quencher dye (NFQ). PCR reactions were 
performed in triplicate under the following conditions: 50oC for 2 min, 95oC for 10 min, 
followed by 40 cycles of 95oC for 15 sec, and 60oC for 1 min. Fluorescence was 
determined on an ABI PRISM 7900HT-sequence detection system (Perkin Elmer, 
Forest City, CA). Data were analyzed using the comparative threshold cycle (Ct) 
method, and results are expressed as fold difference. 
Statistical analysis 
All data were analyzed using the ANOVA routine in Statview and MIXED 
procedure of the Statistical Analysis System software (SAS Inst., Cary, NC). All data 
were subjected to a univariate analysis to ensure normality. Locomotor data was 
subjected to a four-way ANOVA (age × icv × i.p. × time) using repeated measures in 
which time (0, 4, 6, 8, and 24 h) was a within subjects measure, and age (adult or 
aged), sgp130 (vehicle or 100 ng/mouse), and LPS (sterile saline or LPS 10 µg/mouse) 
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were between subjects measures. Weight loss, food intake, microglia and astrocyte 
data were subjected to a three-way ANOVA (age × icv × i.p.). Gene expression data 
were subjected to a three-way ANOVA (age × icv × i.p.) or a t-test (age). Post hoc 
Student’s t test of least square means was used to determine if treatment means were 
significantly different from one another (p<0.05). All data are presented as mean ± 
standard error of the mean (SEM). 
6.4 Results 
 IL-6R and gp130 expression on adult vs. aged microglia and astrocytes 
Studies in our and other labs have demonstrated an exaggerated brain IL-6 
response during infection in aged animals (Godbout and Johnson, 2004; Ye and 
Johnson, 1999b, 2001). We believe that this dysfunctional IL-6 production in the 
senescent brain is attributed to dysregulated IL-6 signaling, and becomes a contributing 
factor to age-related behavioral deficits. Thus, we sought to determine the potential 
effects of trans-signaling on microglia and astrocytes in aging by determining the 
cellular distribution of IL-6R and gp130 on adult and aged glia. We isolated cell 
populations of microglia and astrocytes by percoll density gradient, and all cells were 
subjected to the BD Cytofix/CytopermTM fixation/permeabilization protocol. Microglia 
were stained for CD11b and CD45 and astrocytes were stained for GFAP, and both 
populations were stained for IL-6R and gp130. Figures 6.1A and B, shows the average 
percentage of microglia that were CD11b+/IL-6R+ and CD11b+/gp130+. Microglia from 
aged mice had significantly higher expression of IL-6R compared to adult animals 
(p<0.05), while there was no difference in the expression of gp130. Figures 6.2A and 
6.2B shows the average percentage of astrocytes that were GFAP+/IL-6R+ and 
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GFAP+/gp130+. Contrary to microglia data, there was no significant difference of IL-6R 
expression and there was a visible trend (p=0.283) of higher expression of gp130 on 
astrocytes from aged mice. 
Hippocampal tissue was collected 24 h after i.p. sterile saline and assayed for 
ADAM17 and ADAM10.  Aged animals had a significant upregulation of baseline levels 
of ADAM17 gene expression (p<0.05, Figures 6.3A and 6.3B). Taken together, this data 
suggests the baseline upregulation of IL-6 in the aged is attributed to higher amounts of 
IL-6R shedding that induce higher levels of IL-6 trans-signaling, gene expression, and 
inflammation in the CNS of aged animals.   
 
sgp130 inhibits LPS-induced sickness behaviors in aged animals 
Microglia and astrocytes produce pro-inflammatory cytokines, including IL-6, that 
induce and facilitate sickness behaviors. Given the results from our recent study (Burton 
et al., 2011), we investigated the effects of centrally administered sgp130 on LPS-
induced sickness behavior in the aged. Adult and aged animals were co-administered 
icv sgp130 and i.p. LPS and locomotor behavior, changes in body weight, and food 
intake were used as measures of sickness (Figures 6.4, 6.5, 6.6, and 6.7). Locomotor 
behavior was measured at a baseline (0), 4, 6, 8, and 24 h after injections. As expected, 
icv vehicle and i.p. LPS treatment decreased locomotor behavior in a time-dependent 
manner in both adult and aged animals (p<0.001). LPS induced modest sickness in 
adult mice at 4 h, whereby the depression in locomotor behavior returned to baseline 
level by 24 h post-injection (Figure 6.4).  
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Also consistent with prior studies, icv vehicle and i.p. LPS treated aged mice 
(Figure 6.5) exhibited  an exaggerated impairment through 24 h post injection (Godbout 
et al., 2005b). Interestingly, there was a significant age × sgp130 × LPS interaction 
(p<0.05) where LPS-induced depression of locomotor behavior in aged mice was 
ameliorated by co-administration of icv sgp130, at all time points (Figure 6.5). Important 
to note, icv sgp130 and i.p. LPS animals, displayed a reduction in locomotor activity 
animals at the 4 and 6 h time point, which we attributed to LPS-induced IL-1β 
production. However, when compared to adult animals at 4 and 6 h after LPS injection, 
aged animals showed a dramatically improved sickness response, compared to icv 
vehicle-treated aged animals that had prolonged depressed locomotor behavior 24 h 
after LPS (Figure 6.5).  
There was no significant difference in icv sgp130-treated adult animals, the 
animals remained sick until they recovered 24 h post injection as in the icv vehicle 
treated animals. This data is differs from social exploratory data, in which sgp130 
improves recovery by 8 h in adult animals. It appears as if there is motivational input of 
some sickness behaviors where differences are observed. 
Additionally, sgp130 had significant mitigating effects on LPS-induced reductions 
in food intake and weight loss (Figures 6.6A and B) in aged animals, but not adult 
animals. While sgp130 did not return either behavior to baseline, the exaggeration of 
sickness seen in aging was ameliorated indicating that the response the maladaptive 
response was curbed to adaptive levels. These data suggest that the upregulated IL-6 
trans-signaling pathway is more sensitive in aged animals for the onset of sickness, 
while it is important for maintaining sickness behavior in adult animals.  
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sgp130-mediated LPS-induced microglia production of IL-6 and priming 
To determine the microglial distribution and signaling capacity of IL-6 production 
in the CNS, we determined intracellular IL-6 protein expression in microglia isolated 
from adult and aged mice 6 h after icv sgp130 and i.p. LPS injection. Figure 6.8 shows 
the average percentage of microglia from adult and aged mice stained with anti-CD11b-
APC and intracellular anti-IL-6-PE. As expected, peripheral LPS injection increased the 
percentage of IL-6+ microglia (CD11b+/IL-16+) in both age groups (Figure 6.8). In a 
comparison between LPS-treated adult and aged mice, there was a significant 
difference in the percentage of IL-6+ microglia (CD11b+/IL-6+) in aged mice (p<0.05), an 
observation consistent with earlier findings from our lab (Ye and Johnson, 1999a). 
Figure 6.8 goes on to show that icv sgp130 attenuates IL-6 production from aged 
microglia, taking the levels down similar to that of adult expression levels. While sgp130 
did not completely abrogate the exaggerated expression of IL-6, the maladaptive levels 
seen in aging were curtailed and mirror the observations seen in the sickness behavior, 
to an adaptive response. 
Previous studies have shown that IL-6 induces MHC-II on microglia and trans-
signaling potentiates this affect (Burton, 2012 ). Therefore, we determined if sgp130 
augmented increased MHC-II surface expression on microglia isolated from aged mice. 
Isolated microglia from adult and aged brains, were stained with antibodies for CD11b, 
CD45, and MHC-II, and then analyzed by flow cytometry. Figure 6.9 is the average 
percentage of CD11b+/MHC-II+ cells, and shows consistency with previous that 
microglia isolated from aged mice had significantly higher MHC-II expression 
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(CD11b+/MHC II+) compared to the adult microglia. There was no significant age × 
sgp130 × LPS interaction, although there was a slight decrease of MHC-II in the 
sgp130- treated aged group. A possible explanation for this result is the exposure of 
sgp130 was not sufficient to have a significant effect. Taken together, these cytokine 
protein data indicate that peripheral immune stimulation caused microglia from aged 
mice to become hyper-responsive, and is associated with increased production of IL-6, 
and sgp130 mitigates the hyperactivity. 
 
sgp130-mediated LPS-induced astrocyte production of IL-6  
Previous studies have shown that numbers and markers of astrocyte activation 
do not increase with aging (Ye and Johnson, 1999a), but to date no one has determined 
astrocyte involvement in cytokine production during peripheral infection and aging. To 
determine the astrocyte distribution and signaling capacity of IL-6 production in the 
CNS, we determined intracellular protein expression of IL-6 in astrocytes isolated from 
adult and aged mice 6 h after icv sgp130 and i.p. LPS injection. Figure 6.10 shows the 
average percentage of astrocytes from adult and aged mice stained with anti-GFAP-
Alexa Fluor-488 and intracellular anti-IL-6-PE. Peripheral LPS injection increased the 
percentage of IL-6+ astrocytes (GFAP+/IL-16+) in both age groups (Fig. 6.10). Similar to 
microglia, there was a significantly higher percentage of IL-6+ astrocytes (GFAP+/IL-6+) 
in aged mice compared to adult mice (p<0.05). icv sgp130 attenuates IL-6 production 
from both adult and aged astrocytes, a stark contrast to the microglia data in which only 
the aged microglia were affected. These data indicate that LPS-induced astrocyte-
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derived IL-6 is modulated from microglia and may or may not directly affect sickness 
behaviors.  
Exaggerated IL-6 and MHC-II gene expression is modified by sgp130  
Increased mRNA levels of inflammatory glial markers have been detected in the 
aged brain (Dilger and Johnson, 2008). The action of sgp130 is anticipated at the IL-6 
receptor level, but it is important to assess if it immediately affects other cytokines, 
regulators/modulators of cytokine expression, or the BBB. It is important to assay 
mRNA transcripts as it can indicate a change that would be seen quicker than a change 
in protein levels. In order to assay gene expression the hippocampus was used as a 
representation of the global neuroinflammatory response and various markers of 
inflammation (IL-1β, IL-6,), oxidative stress (iNOS2), cytokine signal regulation (SOCS1 
and SOCS3), cytokine modulation (ADAM10 and ADAM17), and markers of BBB 
integrity (ICAM-1 and VCAM-1) were measured. 
A number of studies correlate exaggerated IL-6 mRNA levels with alterations in 
behavioral process (Bellinger et al., 1995; Gruol and Nelson, 1997; Maggio et al., 2006; 
Weaver et al., 2002). With the robust effects of sgp130 inhibition of LPS-induced 
sickness behavior, IL-6 protein in microglia and astrocytes in aged animals, we were 
interested in the effect of IL-6 trans-signaling inhibition on IL-6 gene expression. Adult 
and aged mice received co-administration of sgp130 (icv) and LPS (i.p.) and 
hippocampal tissue was harvested 6 h after. Figure 6.11A shows data similar to protein 
levels. There was a significant age × sgp130 × LPS interaction (p<0.05), whereby 
sgp130 significantly decreased the basal and LPS-induced expression of IL-6 in the 
aged brain, and showing a decreasing trend in the adult. 
157 
 
Based on the findings of sgp130-mediated MHC-II protein expression, we 
measured gene expression, as timing dictates that gene expression would be first 
affected in altering MHC-II. Interestingly, sgp130 significantly decreased the basal age-
associated upregulation MHC-II gene expression (p<0.05, Figure 6.11B). Taken 
together, these results further validate that sgp130 is working at the receptor level and 
IL-6 trans-signaling is involved in microglia priming.  
 
sgp130 does not affect oxidative stress, cytokine regulators, modulators or BBB 
sgp130-mediated decrease of LPS-induced IL-6 mRNA in the hippocampus may 
have other consequences that could account for the alterations in sickness behavior 
and microglial hyperactivity. Figures 6.12 – 6.15 show, IL-1β and iNOS2, ADAM17 and 
ADAM10, SOCS1 and SOCS3, and ICAM-1 and VCAM-I, respectively.  Overall, there 
was no significant sgp130 × age × LPS interaction for any of the above genes. 
However, worth mentioning, icv sgp130 decreased i.p. LPS-induced IL-1β (Figure 
6.12A) and VCAM-1 (Figure 6.15B) expression of aged animals to similar expression 
levels of adult animals, but not significantly different than icv vehicle treated age- 
matched animals. This could indicate the well documented IL-1β and IL-6 interaction 
and bi-directional influence (Tosato and Jones, 1990).  Also noteworthy is the age-
dependent basal upregulation of adhesion molecules ICAM-1 and VCAM-1, perhaps 
indicative of more traffic across the BBB during aging, or potentially to compensate for a 
loss of protein (Mooradian, 1988). While expression of these genes is not altered at this 
time point, the initial window of sgp130 effectiveness may manifest downstream 
changes. Taken together, these results show that sgp130-related changes in LPS-
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induced sickness behavior are paralleled by sgp130-associated changes of IL-6 in cells 
of the brain.  
6.5 Discussion  
The bi-directional communication between the periphery and the brain is 
essential to mount the appropriate response to an immune stimulus (Dantzer et al., 
1998). However, in aging this physiological response turns to a pathological state as 
there is excessive cytokine production in the brain in response to a peripheral immune 
stimulus (Godbout and Johnson, 2009). This pathological production of cytokines are 
coupled with an increase of behavioral deficits (Dilger and Johnson, 2008). Excessive 
pro-inflammatory IL-6 in the brain plays a critical role in the development of these 
infection-related alterations in sickness behavior and cognition (Bluthe et al., 2000; 
Burton and Johnson, 2011; Maggio et al., 2006). Here, we extended our previous work 
on IL-6 production in the aged brain, and begin to elucidate a mechanism for 
exaggerated levels in the brain. First we showed that aged microglia expressed a higher 
level of IL-6R (Figure 6.1A) and the aged brain expressed higher ADAM17 sheddase 
(Figure 6.3A), than adult animals. This data suggests that microglia are primarily 
responsible for shedding IL-6R and inducing the IL-6 trans-signaling in the 
microenvironment of the CNS. Similar observations have been documented in models 
of peripheral inflammation and colon cancer, the researchers found upregulated IL-6R 
on T-cells and an increase in ADAM17, alluding to IL-6 trans-signaling is involved in 
immune cell regulation and disease (Becker et al., 2004). 
The idea is that age-dependent upregulation of IL-6 trans-signaling is facilitated 
through a receptor stimulated STAT3-dependent mechanism of feed-forward IL-6 
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production in the brain of aged animals (Burton and Johnson, 2011) before and during 
peripheral stimulation. We therefore investigated the effects of icv sgp130 and 
hypothesized that, given the role of IL-6 in neuroinflammatory responses; sgp130 would 
attenuate LPS-induced sickness behavior and IL-6 production. sgp130 was effective in 
inhibiting the onset of LPS-induced depression of locomotor behavior as well as LPS-
induced anorexia and reduction in food intake in aged mice. Moreover, we showed that 
icv sgp130 inhibited LPS-induced sickness in aged animals, and these sgp130-
associated effects were paralleled by reduced mRNA transcript in the hippocampus, 
and protein levels of IL-6 in microglia and astrocytes. 
Consistent with previous studies, a reduction in brain IL-6 did not completely 
prevent the initial induction of LPS-induced sickness behavior seen at 4 h post-injection 
in adult animals, (Abraham and Johnson, 2009a; Berg et al., 2004; Godbout et al., 
2004; Godbout et al., 2005a; Henry et al., 2008), and this is the case because LPS is 
such a potent immune stimulus. Moreover, the amelioration of the exaggerated LPS-
induced behavioral deficits seen in aging has been observed in various nutritional and 
pharmacological interventions and our observations are consistent with previous studies 
(Abraham and Johnson, 2009a; Berg et al., 2005; Burton and Johnson, 2011; Richwine 
et al., 2005). These data suggest that aged animals are more sensitive to changes in 
pro-inflammatory mediators, foreseeable going from maladaptive to adaptive levels. 
This inhibition of LPS-induced sickness in aged mice may be of particular 
importance when considering conditions where an exaggerated response is elicited 
during a primed inflammatory state, such as in overexpressing transgenic animals 
(Campbell et al., 1993; Heyser et al., 1997), prion disease (Combrinck et al., 2002), and 
160 
 
neurodegenerative diseases (Betmouni et al., 1996; Cunningham et al., 2005; Du et al., 
2001; Hofmann et al., 2009; Perry et al., 2003). We have previously demonstrated that 
aged animals display an exaggerated neuroinflammatory and sickness behavior 
response after activation of the peripheral immune system (Godbout et al., 2005b), and 
it appears that primed microglia are responsible for this exacerbated phenotype 
(Godbout et al., 2004; Sparkman and Johnson, 2008; Ye and Johnson, 1999b). Current 
data beings to uncover that astrocytes also have a role in IL-6 production in the aged 
system. 
Successful activation of the IL-6/IL-6R complex results in enhanced production of 
IL-6 and blocking this pathway with sgp130 will reduce the production of IL-6 and other 
proteins that interact with IL-6. The present study demonstrates that the exaggerated 
levels of LPS-induced IL-6 in aging are associated with IL-6 trans-signaling and higher 
levels of the sheddase ADAM17.  However at the time point of 6 h after sgp130 and 
LPS treatment, gene expression of cytokine regulators, modulators, oxidative stress, 
and BBB were left essentially unaltered. IL-6 is predominately the protein that is 
affected in this system proving the importance of the protein.  
A recent study found an IL-6 trans-signaling-mediated crosstalk between the 
TLR-4 and STAT3 pathway to reveal trans-signaling is implicated in pro-inflammatory 
action versus classical signaling (Greenhill et al., 2011). Using sgp130 allowed us to 
investigate the effects of IL-6 after LPS treatment, while leaving all other cytokines 
unaffected.  
We and other groups have shown that anti-inflammatory interventions are able to 
ameliorate the exaggerated cytokine as well as the maladaptive response that results 
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from peripheral infection in aged individuals (Abraham and Johnson, 2009a, b; Berg et 
al., 2005; Henry et al., 2008; Jang et al., 2010; Richwine et al., 2005). These data agree 
with other studies using sgp130 to inhibit IL-6 signaling in peripheral models of 
inflammation, such as arthritis, peritonitis, and colitis (Coles et al., 2007; McLoughlin et 
al., 2005; Richards et al., 2006). To our knowledge, this is the first study to report that 
co-administration with sgp130 attenuates LPS-induced exaggerations in sickness and 
IL-6 protein production in microglia and astrocytes in aged animals. Studies have 
highlighted the potential therapeutic role of sgp130 in treating peripheral inflammatory 
conditions; as well as to suppress the severity of EAE and modulate neutrophil 
trafficking (Atreya et al., 2000; Chen et al., 2004; Fielding et al., 2008; Linker et al., 
2008). The current study is the first to extend the body of literature and show the 
effectiveness of sgp130 in inhibiting IL-6 signaling in cells of the aged CNS. Taken 
together, the present study suggests that the use of sgp130 as an inhibitor of the IL-6 
pathway in an array of inflammatory conditions, from peripheral to neurodegenerative 
disease, mitigates IL-6 expression and has a beneficial effect on sickness-related 
behavioral responses.  
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Figure 6.1: Differential expression of IL-6 receptor and gp130 on microglia isolated 
from adult and aged mice. Average percentage of cells that were A) CD11b+/IL-6R+ B) 
and CD11b+/gp130+. Cell surface markers were assessed for CD11b, CD45, and IL-6R or 
gp130 expression; compared with isotype and unstained controls. Bars represent the 
means ± SEM (n = 8). Means marked with a * are significantly different from each other 
(p<0.05). 
 
 
 
A. 
B. 
163 
 
Astrocyte IL-6R
0
10
20
30
Adult Aged
%
 G
FA
P+
/IL
-6
R
+
Astrocyte gp130
0
10
20
30
Adult Aged
p=0.283
%
 G
FA
P+
/g
p1
30
+
 
Figure 6.2: Differential expression of IL-6 receptor and gp130 on astrocytes isolated 
from adult and aged mice. Average percentage of cells that were A) GFAP+/IL-6R+ B) and 
GFAP+/gp130+. Cell surface markers were assessed for GFAP and IL-6R or gp130 
expression; compared with isotype and unstained controls. Bars represent the 
means ± SEM (n = 8). Means marked with a * are significantly different from each other 
(p<0.05). 
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Figure 6.3: Hippocampal gene expression of IL-6 receptor sheddases ADAM17 and 
ADAM10 from adult and aged mice. Hippocampal tissue was collected 24 h after i.p. sterile 
saline and assayed for A) ADAM17 and B) ADAM10.  Aged animals had a significant 
upregulation of baseline levels of ADAM17 gene expression. Bars represent the mean ± SEM (n 
= 8-9) Means with * are statistically different from each other (p<0.05). 
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Figure 6.4: sgp130-mediated LPS-induced sickness behavior in adult animals. Mice were 
injected icv with vehicle or sgp130 (100ng) and i.p. with sterile saline or LPS (10 µg). 
Spontaneous locomotor baseline behavior was measured before injections (0) and at 4, 6, 8, 
and 24 h post-injection. Bars represent the mean ± SEM (n = 10-11) Means with * are 
statistically different (p<0.05) from saline controls. 
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Figure 6.5: sgp130-mediated LPS-induced sickness behavior in adult animals. Mice 
were injected icv with vehicle or sgp130 (100ng) and i.p. with sterile saline or LPS (10 µg). 
A) Body and B) food weight was measured before LPS injection and at 24 h post-injection. 
Bars represent the mean ± SEM (n = 10-11) Means with * are statistically different (p<0.05) 
from saline controls. 
A. 
B. 
167 
 
 
 
 
 
Aged Locomotor
0 h 4 h 6 h 8 h 24 h 
0
20
40
60
80
100
120
140
* *
* *
Vehicle/Saline Vehicle/LPS sgp130/Saline sgp130/LPS
Time post  LPS (h)
Di
st
an
ce
 M
ov
ed
 (%
 B
as
el
in
e)
 
 
Figure 6.6: sgp130-mediated LPS-induced sickness behavior in aged animals. Mice 
were injected icv with vehicle or sgp130 (100ng) and i.p. with sterile saline or LPS (10 µg). 
Spontaneous locomotor baseline behavior was measured before injections (0) and at 4, 6, 
8, and 24 h post-injection. Bars represent the mean ± SEM (n = 10-12). Means with 
different letters are statistically different (p<0.05) from vehicle/saline controls. 
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Figure 6.7: sgp130-mediated LPS-induced sickness behavior in aged animals. Mice 
were injected icv with vehicle or sgp130 (100ng) and i.p. with sterile saline or LPS (10 µg). 
A) Body and B) food weight was measured before LPS injection and at 24 h post-injection. 
Bars represent the mean ± SEM (n = 10-11). Means with different letters are statistically 
different (p<0.05) from vehicle/saline controls. 
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Figure 6.8: sgp130 augments LPS-induced microglial IL-6 production in the aged.  
Adult and aged mice were injected icv with vehicle or sgp130 (100ng) and i.p. with sterile 
saline or LPS (10 µg) and microglia were isolated 6 h later by percoll density gradient. Cells 
were subjected to the BD Cytofix/CytopermTM fixation/permeabilization protocol and stained 
with anti-CD11b-APC, anti-CD45-FITC, and anti-IL-6-PE. Average percentage of cells that 
were CD11b+/IL-6+. Bars represent the means ± SEM (n =7-8). Means with different letters 
are statistically different (p<0.05) from each other. 
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Figure 6.9: Microglial MHC-II expression on adult and aged mice.  Adult and aged mice 
were injected icv with vehicle or sgp130 (100ng) and i.p. with sterile saline or LPS (10 µg) 
and microglia were isolated 6 h later by percoll density gradient. Cells were subjected to the 
BD Cytofix/CytopermTM fixation/permeabilization protocol and stained with anti-CD11b-APC, 
anti-CD45-FITC, and anti-MHC-II-PE. Average percentage of cells that were CD11b+/MHC-
II+. Bars represent the means ± SEM (n =7-8). Means with different letters are statistically 
different (p<0.05) from each other. 
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Figure 6.10: sgp130 augments LPS-induced astrocyte l IL-6 production in the aged.  
Adult and aged mice were injected icv with vehicle or sgp130 (100ng) and i.p. with sterile 
saline or LPS (10 µg) and astrocytes were isolated 6 h later by percoll density gradient. 
Cells were subjected to the BD Cytofix/CytopermTM fixation/permeabilization protocol and 
stained with anti-GFAP-Alexa Fluor 488 and anti-IL-6-PE. Average percentage of cells that 
were GFAP+/IL-6+. Bars represent the means ± SEM (n =7-8). Means with different letters 
are statistically different (p<0.05) from each other. 
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Figure 6.11: sgp130-mediated LPS-induced hippocampal gene expression of IL-6 and 
MHC-II from adult and aged mice. Adult and aged mice were injected icv with vehicle or 
sgp130 (100ng) and  i.p. with sterile saline or LPS (10 µg) and hippocampal tissue was 
collected  8 h later and assayed for A) IL-6 and B) MHC-II.  Bars represent the mean ± SEM 
(n = 7-8) Means with different letters are statistically different (p<0.05) from each other. 
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Figure 6.12: sgp130-mediated LPS-induced hippocampal gene expression of IL-1β 
and iNOS2 from adult and aged mice. Adult and aged mice were injected icv with vehicle 
or sgp130 (100ng) and  i.p. with sterile saline or LPS (10 µg) and hippocampal tissue was 
collected  8 h later and assayed for A) IL-1β and B) iNOS2.  Bars represent the mean ± 
SEM (n = 7-8) Means with different letters are statistically different (p<0.05) from each 
other. 
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Figure 6.13: sgp130-mediated LPS-induced hippocampal gene expression of ADAM17 
and ADAM10 from adult and aged mice. Adult and aged mice were injected icv with 
vehicle or sgp130 (100ng) and  i.p. with sterile saline or LPS (10 µg) and hippocampal 
tissue was collected  8 h later and assayed for A) ADAM17 and B) ADAM10.  Bars 
represent the mean ± SEM (n = 7-8) Means with different letters are statistically different 
(p<0.05) from each other. 
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Figure 6.14: sgp130-mediated LPS-induced hippocampal gene expression of SOCS1 
and SOCS3 from adult and aged mice. Adult and aged mice were injected icv with vehicle 
or sgp130 (100ng) and  i.p. with sterile saline or LPS (10 µg) and hippocampal tissue was 
collected  8 h later and assayed for A) SOCS1 and B) SOCS3.  Bars represent the mean ± 
SEM (n = 7-8) Means with different letters are statistically different (p<0.05) from each 
other. 
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Figure 6.15: sgp130-mediated LPS-induced hippocampal gene expression of ICAM-1 
and VCAM-1 from adult and aged mice. Adult and aged mice were injected icv with 
vehicle or sgp130 (100ng) and  i.p. with sterile saline or LPS (10 µg) and hippocampal 
tissue was collected  8 h later and assayed for A) ICAM-1 and B) VCAM-1.  Bars represent 
the mean ± SEM (n = 7-8) Means with different letters are statistically different (p<0.05) 
from each other. 
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Chapter 7 
Summary and Significance 
The rapid growth of the aged population, along with healthcare reform and cost 
associated with supporting the aged, makes research on the pathogenesis of aging a 
vital concern to society. The U.S. census bureau projects that individuals aged 65 years 
and older will account for roughly 30% of the total population by 2050; up from about 
10% in 2010 (U.S. Census). With this growing aging population, the prevalence of age-
related diseases with an inflammatory component (e.g.arthritis, Alzheimer’s disease, 
diabetes, cardiovascular disease) increases. Indeed, in the brain of aged animals, there 
is a baseline upregulation of pro-inflammatory cytokines, which are further exaggerated 
during peripheral infection when compared to young adult animals. Our lab and others 
have shown this exacerbated cytokine response in the brain of aged animals plays a 
critical role in infection-related behavioral pathology (Brod, 2000; Burton and Johnson, 
2011; Burton, 2012 ; Burton et al., 2011; Chen et al., 2008; Gallagher et al., 2006; 
Gallagher et al., 1996; Godbout et al., 2005; Godbout et al., 2008).  
 In recent years, the numbers of publications centered on aging and 
neurodegeneration have steadily increased. With this increase, the focus on neuro-
modulatory pathways has come into the forefront and glial cells and inflammatory 
processes in the brain are principal subjects of investigation. The central nervous 
system (CNS) had been typically regarded as an immunologically privileged site, though 
a plethora of studies have provided evidence that the peripheral immune system 
communicates an immune signal to the CNS via neural, humoral, and diffusive 
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pathways. This signal comes in the form of cytokines, which play a crucial role in the 
initiation, propagation, regulation, and suppression of immune and inflammatory 
processes. Pro-inflammatory cytokines such as IL-1β, TNF-α, and IL-6 are the 
prototypic molecules that are of particular interest in CNS inflammation and 
pathogenesis of neurodegenerative disease. 
There is a correlation with the over production IL-6 during aging and 
development of neurodegenerative diseases, such as Alzheimer’s and Multiple 
Sclerosis (De Luigi et al., 2001; Gruol and Nelson, 1997; Licastro et al., 2003), and we 
believe the excessive production of IL-6 in the brain may underlie cognitive deficits that 
are highly prevalent in elderly patients. However IL-6 is implicated in pro- and anti-
inflammatory processes. The data presented suggests that IL-6 trans-signaling is 
involved in the pro-inflammatory arm of IL-6 production in the CNS and that the use of 
sgp130 as an inhibitor of this pathway in an array of inflammatory conditions, from 
peripheral to neurodegenerative disease, mitigates IL-6 expression and has a beneficial 
effect on sickness-related behavioral and cognitive deficits. 
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